Michael Jordan and His Massive Gambling Habit

A not-so-brief rundown of the letters N-Q in Jeffrey Epstein's 'Little Black Book'

Below is a rundown of the letters N-Q under Epstein's contacts. Last year, I wrote about letters A-C. You can check that out here (https://www.reddit.com/conspiracy/comments/cpis3n/a_brief_rundown_of_the_first_ten_pages_of_jeffrey/).
I also wrote about letters D-F on July 5, 2020. You can check that out here (https://www.reddit.com/conspiracy/comments/hlrba8/a_notsobrief_rundown_of_letters_df_in_jeffrey/).
I posted letters G-I on July 13, 2020. You can check that out here (https://www.reddit.com/conspiracy/comments/hqko0y/a_notsobrief_rundown_of_letters_gi_in_jeffrey/).
I posted letters J-L on July 15, 2020. You can check that out here (https://www.reddit.com/conspiracy/comments/hrq9bg/a_notsobrief_rundown_of_letters_jl_of_jeffrey/).
I posted letter M on July 20, 2020. You can check that out here (https://www.reddit.com/conspiracy/comments/huw0yt/a_notsobrief_rundown_of_the_letter_m_in_jeffrey/). There are some misspelled names. Epstein entered their names like this.
I have bolded some of the more interesting connections and information, but there could be much more that I overlooked. I hope something here strikes an interest in someone and maybe we can get more investigations out of this. Please, if you know anything more about any of these people than what is presented here, post below. I am working off of the unredacted black book found here: https://www.coreysdigs.com/wp-content/uploads/2019/07/Jeffrey-Epsteins-Little-Black-Book-unredacted.pdf
N
Nadler, Emanuel: Businessman involved in mortgage companies.
Nagel, Adam: Works at W Nagel, broker and advisor to premier diamond manufacturers, such as De Beers.
Nagel, William: Chairman of W Nagel. Diamond merchant.
Nardi, Dott M Jacope: No info found.
Nastasse, Ilie & Alex: Ilie was one of the best professional tennis players in the ‘70s. He has been accused of inappropriate behavior by Maria Shriver and others, although this refers to classless comments not physical abuse. Ilie is also well-known for his sexual exploits, as it claimed that he has slept with anywhere between 800-900 women. Alexandra is Ilie’s 2nd wife. They were married for 17 years.
Negrete, Jelitza: A Countess and descendant of European nobility (http://www.almanachdegotha.org/id197.html). Her family name is Karolyi. I couldn’t find any more info.
Neil, Andrew: British journalist and broadcaster. Founding Chairman of Sky TV (owned by Murdoch). Also served as Editor for Rupert Murdoch’s The Sunday Times from ‘83-’94. Later became a contributor to The Daily Mail and just recently had his political program cancelled by the BBC.
Neil, Andrew: Same as above.
Newman, Hetty: Second wife of the 7th Earl of Caledon. Now divorced.
Newman, Mr & Mrs John: John is Hetty’s father. He achieved the rank of Lieutenant in the Royal Horse Guards. He later became a businessman and was director of several companies.
Ng, Clive: A media financier and executive.
Niarchos, Constantine: Billionaire son of shipping magnate Stavros Niarchos. Was once married to Alessandra Borghese of Italian papal lineage (and black nobility). He was also romantically linked to Koo Stark, Trinny Woodhall, and Kerry Kennedy (daughter of Bobby Kennedy), all of whom are in Epstein’s ‘black book’. Constantine died of an overdose with enough cocaine in his system to kill 25 men (https://www.theguardian.com/theobserve1999/oct/17/life1.lifemagazine7).
Nickerson, William & Jayne: William seems to be an architect and interior designer. Jayne is a fashion editostylist who is friends with Naomi Campbell (https://www.dailymail.co.uk/femail/article-7645409/Jayne-Pickering-asks-expert-designer-wardrobe-actually-nest-egg.html). Her and William are now divorced.
Nishio, Yoshi: Former Goldman Sachs trader.
Noel, Alix: Socialite married to a wealthy banker. Friend of Allegra Hicks, who has constantly popped up among Epstein’s contacts.
Noel, Hon Thomas: Son of Anthony Noel, 5th Earl of Gainsborough.
Noel, Vanessa: Luxury shoe designer, hotelier, and gallery owner. Many celebrities are clients of hers.
Noha, Cecilia: Possibly meant to be Cecilia Noah, former Miss Sweden (1978).
Noonan, Tim: Tax lawyer.
Nuttall, Harry: Former Formula One driver turned sports marketing entrepreneur.
O’Donnell, Mr Carletto: Financier. Friend of Princess Michael of Kent (King George V’s grandson).
O’Neill, Louis: An American diplomat and attorney. Has worked for the Organization for Security and Co-operation in Europe (OSCE), the Obama administration, the State Department, and as Special Assistant of Russian Affairs for Colin Powell.
Oates, Simon: British actor who died in 2009.
Oates, Tom: Former investment director at BlackRock, an investment management company.
Ojora, Yinka: CEO and/or Director of a number of investing groups in Nigeria.
Olsen, Camille: Friend of Ghislaine Maxwell (https://www.gettyimages.co.uk/detail/news-photo/leilani-johnson-donna-dcruz-patricia-vel%C3%A1squez-ghislaine-news-photo/1169681661?adppopup=true). Don’t know much else, but she has been photographed at these high society parties fairly frequently.
Omar, Ralph: No info found.
Ong BS & Chritina: Christina is a Singaporean hoteliebusinesswoman who is heavily involved with Club 21 (a luxury fashion brand) and COMO Hotels and Resorts. She runs all of the Armani outlets in Britain, as well as the franchises for Donna Karan, Prada, and Bvlgari. Christina and her husband, Beng Seng, are worth $1.9 billion.
Ong, Melissa: Christina and BS’s daughter.
Oppenheim, Mr Laurie: Oppenheim worked as an executive at Marks and Spencer, a British retail chain, for nearly 30 years. Oppenheim has also served as a Trustee for a children’s charity called… The Honeypot Children’s Charity (https://www.honeypot.org.uk/what-we-do/meet-the-team/#our-trustees) since 1998 (https://uk.linkedin.com/in/laurie-oppenheim-22ab7512?challengeId=AQGP2jc2VAYQXwAAAXN6h0UrQXFHXyzrAP28ks5TK1rXMSHM5kNgtLMIfKERVP65UG0_eg9Az_1EjABS1pQqIpz9a69ZXhKpVw&submissionId=2923537f-6250-2416-4d31-f9585e45dc7b). I wish I was kidding. That’s the actual name. Oppenheim was also one of the attendees of an auction for the children’s charity, KIDS (https://www.tatler.com/gallery/wallace-collection-fundraiser), which is populated with Epstein contacts Rosa Monckton and Liz Hurley, and other high profile people such as David Cameron, Elton John, David Furnish, Cherie Booth, and Cathy Newman. The auction was led by Jacob Rothschild. Other attendees that also appear in Epstein’s contacts include Lady Forte (Allai Forte) and Arpad Busson, one of the potential pedophile ringleaders who I wrote about last year (https://www.reddit.com/conspiracy/comments/cl34ju/arpad_busson_billionaire_businessman_or_possible/).
Oppenheim, Ms Marella: This likely refers to the documentary photographer and former journalist of The Guardian.
Orchard (Vaughn-Edward), Katie: Catherine is a very close friend of Ghislaine Maxwell’s. She allowed Ghislaine to use her address as the business address for the TerraMar Project, a charity that Maxwell created. Catherine also served as Trustee and co-director of the charity (https://www.tatler.com/article/where-on-earth-is-ghislaine-maxwell).
Orlando, Fabrice: CEO of Cocoon Events Management Group, a luxury event planning company based out of Morocco.
Osbourne Rachel: British businesswoman who has served as director for several companies.
Oswald, William & Arabella: William co-founded Twins (https://twins.org.uk/governance/), a children’s charity that “links UK schools with schools in areas hit by natural disasters and/or need, both for practical support and for cultural understanding” (https://twins.org.uk/). William works as a director at several companies, including Keyspace Self Storage, Bluepod Media, and SG Capital Partners. William’s father is the National Hunt racing adviser to the Queen, and before that, the Queen Mother. Arabella is his wife and the daughter of the 6th Marquess of Exeter.
Otto, Beo & Edvige: Not positive. Seems that Edwige works in stock trading in France (if I have the correct person). No info on Beo.
Owen Edmunds, Tom & Kate: Kate is a novelist. Her ex-husband, Tom, is a photographer.
Oxenberg Christina marc Yaggi: Christina is a writer and fashion designer. Her mother is Princess Elizabeth of Yugoslavia. Her grandparents were Prince Paul of Yugoslavia and Princess Olga of Greece and Denmark. Due to all of the inbreeding between European royals, Christine is a cousin of the Royal Family. Oxenberg used to attend dinner parties at Epstein’s and was also friends with Ghislaine (https://www.townandcountrymag.com/society/tradition/a30222833/christina-oxenberg-instagram-patreon-memoi). Oxenberg intends to talk to the FBI about Epstein and Maxwell (https://www.tatler.com/article/christina-oxenberg-speaks-to-fbi-about-ghislaine-maxwell-and-jeffrey-epstein). Marc Yaggi is Executive Director of Waterkeeper Alliance, where Oxenberg was once a writer.
Paini, Nicole: Nicola is a Managing Partner at Rothschild & Co (https://app.mergerlinks.com/people/nicola-paini).
Palau, Marcia: No info found, although her address indicates that she is wealthy. Cheyne Walk is a street that politicians, musicians, and celebrities have all called home.
Palmer Tomkinson Tara: Socialite and TV personality with tons of A-list contacts. Her family is very close with the Royal Family. Tara was a cocaine addict who eventually died of an ulcer in 2017. Prince Charles was her godfather.
Palumbo, Mr James: Baron Palumbo of Southwark is an entrepreneur and a member of the House of Lords. Co-founder of Ministry of Sound nightclub. Major donor to the Liberal Democrats political party.
Palumbo, Peter: Father of James (above). Baron Palumbo is a property developer who sat on the House of Lords from 1991-2019. Former polo teammate and close friend of Prince Charles until they had a falling out. Confidant of Princess Diana. Godfather of Princess Beatrice of York, the elder daughter of Prince Andrew. Peter denies ever having met Epstein.
Panah-Izadi, Nader & Brigitte: Nader is an investment manager. Brigitte is his wife. Couldn’t find anything else.
Pank, Ms Victoria & Alby Carto: No info found.
Parker, Jackie: Management consultant who sits on the board of several companies. Also the head of global philanthropy for General Motors.
Parsons, Carolina: A Chilean model and model scout who has worked for big name designers. Here she is with her friend, Naomi Campbell (https://twitter.com/caroparsons/status/605883012492886016/photo/1). She can also be seen in a picture with Harvey Weinstein at the bottom of this article (https://www.biobiochile.cl/noticias/espectaculos-y-tv/notas-espectaculos-tv/2020/06/01/carolina-parsons-niega-tajantemente-conocer-a-epstein-tras-aparecer-en-supuesta-lista-de-contactos.shtml), which posts her claims that she never knew Epstein.
Paschan, Elise: Famous poet.
Pashcow, Joel: Real estate magnate. He is a past trustee of the Children’s Medical Center at Long Island Jewish Hospital and trustee at ACLD, a charity for developmentally disabled children and adults. He is also on the Board of Directors of the Palm Beach police and fire foundation (https://www.palmbeachpoliceandfirefoundation.org/joel-m-pashcow-bio). Pashcow has flown on Epstein’s jets (https://i.redd.it/hcfoxsb8feb51.png) and has been to pedo island. In fact, Pashcow appears 8 times(!!) on one this released flight log, including once with his wife (https://archive.org/stream/EpsteinFlightLogsLolitaExpress/Jeffrey-Epstein-Flight-Logs-in-PDF-format_djvu.txt). Epstein has 19 entries for Pashcow in his ‘black book’. Here is Pashcow at the Policeman’s Ball, which Trump frequently hosts at Mar-A-Lago (https://westpalmbeach.floridaweekly.com/articles/10th-annual-policemans-ball-mar-a-lago-club-palm-beach/). Pashcow is a ‘Crystal Sponsor’ of the Palm Beach Police Foundation alongside Donald Trump (https://trustedpartner.azureedge.net/docs/pbpolicefoundation2017/news/PBPF_Newsletter_Winter_Spring_2015_TGOFPNMX.pdf).
Pashcow, Stacey: Joel Pashcow’s daughter. A luxury real estate agent for The Corcoran Group. Here’s Stacey at a Valentino-hosted luncheon. Ghislaine Maxwell was also in attendance (https://guestofaguest.com/new-york/fashion/valentino-whets-appetite-for-food-and-fashion-at-fallwinter-2009-capsule-collection-preview-luncheon).
Pastrana, Andres: Former president of Colombia (1998-2002). His father was president of Colombia from 1970-1974). Pastrana was forced to admit flying on Epstein’s ‘Lolita Express’ after the flight logs were released (https://colombiareports.com/colombias-former-president-on-jeffrey-epsteins-lolita-jet-flight-logbook/). According to this article, Ghislaine Maxwell claims to have flown a Blackhawk helicopter in Colombia and fired a rocket into a terrorist camp (https://observer.com/2002/11/vikram-chatwal-turban-cowboy/). There is no time period for when this supposedly occurred, but it could have happened while Pastrana was president.
Patricof, Alan & Susan: Alan is an investor, venture capitalist, and private equity magnate. Patricof served as the national finance chairman for Hillary Clinton’s 2008 campaign (https://www.nytimes.com/2008/04/20/us/politics/20donor.html?scp=19&sq=alan%20patricof&st=cse). From 1990-2016, the Patricofs donated $1,152,637 to Hillary’s campaigns (https://www.opensecrets.org/pres16/bundlers). Alan is also a trusted friend of Jared Kushner, Donald Trump’s son-in-law (https://www.politico.com/story/2017/06/29/jared-kushner-inner-circle-confidants-240116), proving once again that PARTISANSHIP IS BULLSHIT. THEY ARE ALL CONNECTED. Susan is his 2nd wife. Her brother, Craig Hatkoff, appears in Epstein’s contacts under ‘H’. Alan and Susan’s son, Jonathan, is President of Tribeca Enterprises, the company that owns and operates the Tribeca Film Festival. Their other son, Jamie, is a TV and movie producer. His wife, Kelly Sawyer Patricof, is the co-founder of Baby2Baby (https://baby2baby.org/who-we-are/#team), a children’s charity that helps children (0-12) living in poverty.
Paulson, John: Billionaire hedge fund manager.
Pavoncelli, Cosima & Riccardo: Cosima is a socialite and the daughter of Claus and Sunny von Bulow. Her husband, Riccardo, is an Italian banker.
Pearson Hon Charles: Son of the Third Viscount Cowdray and owner of the 53,000 acre Dunecht estate.
Pease, Simon & Clem: Simon was a successful custodian of the family’s Underley Estate. He was also a High Sheriff of Cumbria. Passed away in 2007. Clementine was his wife.
Pedrini Lorenzo: President and co-partner of Fashion Model Management. Pedrini is former Co-President at Next Management, where he was a partner along with Faith Kates and (alleged) pedophile/accomplice/supplier, Jean-Luc Brunel (https://www.thedailybeast.com/jeffrey-epsteins-ties-to-the-modeling-industry-go-much-deeper-than-victorias-secret).
Pedrini Tito: Jeweller.
Pekeler, Marcus: Communications consultant in Switzerland.
Peltz, Harlan: Co-founder of iBorrow, a private commercial real estate lender. Literally lives around the block from Epstein’s NYC mansion.
Pennell, Mark: Australian movie produceactor.
Perelman, Ronald: Billionaire investor. Perelman hosted a dinner party with Epstein, Bill Clinton, Don Fowler, Don Johnson, and Jimmy Buffett all the way back in 1995, when Clinton was still president (https://www.ntd.com/bill-clinton-dined-with-jeffrey-epstein-in-1995-predating-public-timeline-report_355103.html). Perelman is also a good friend of Donald Trump and has given hundreds of thousands of dollars to his campaign. Lives about a half mile away from Epstein’s NYC mansion.
Petangi, Helsius: Son of Ivo Pitanguy, plastic surgeon to the stars.
Peters, John: Movie producer and former hairdresser. He produced Superman Returns (2006), which was directed by (alleged) sexual abuser Bryan Singer. In 2011, Peters had to pay a former assistant $3.3 million after finding that she was sexually harassed during production of Superman Returns. Peters married Pamela Anderson earlier this year, but they separated after 12 days.
Peterson, Holly: Journalist, novelist, and producer for ABC News. Friends with CNN host (and brother of Governor Andrew Cuomo) Chris Cuomo’s wife (https://pagesix.com/2014/08/22/more-than-1m-in-jewels-on-display-at-hamptons-tea-party/). This is the 2nd connection to the Cuomos in Epstein’s contacts. He has Andrew Cuomo and ex-wife Kerry Kennedy listed as well. Ghislaine attended a party to celebrate one of Holly’s books (https://www.gettyimages.com/detail/news-photo/ghislaine-maxwell-caryn-zucker-peter-brown-and-barbara-news-photo/1169681635?adppopup=true).
Peterson, Riki: Not enough info. Best guess is an investment banker of the same name.
Pham Linh-Dan + Andrew: Linh-Dan is a Vietnamese actress. Her husband, Andrew, is an investment banker.
Picasso, Olivier & Alice: Olivier is the grandson of Pablo Picasso. Alice is an actress and Olivier’s former fiance.
Picciotto, Michael: Vice-Chairman at Engels & Volkers AG, a real estate firm. Former head of global financial activities for UBP, a Swiss private bank owned by Picciotto’s family.
Pickering, Jane & William: Jayne is a very famous fashion editor. William is her ex-husband.
Pignatelli, Frederico: An Italian prince whose family has “aristocratic ties to Pope Innocenzo XII” (https://federicopignatelli.com/). President, owner, and founder of Pier 59 Studios, the world’s largest photo studio complex. Federico was once accused of sexual harassment by his former assistant, but he was acquitted (https://nymag.com/intelligence2010/08/photography_studio_head_federi.html). Pignatelli also has his own modeling agency which is headed by Brunella Casella, the woman responsible for launching the career of scumbag Naomi Campbell, Cindy Crawford, and others (https://wwd.com/fashion-news/fashion-scoops/industry-model-management-new-york-office-10505934/).
Pigozzi, Jean: Heir to the CEO of Simca, a French automaker. Pigozzi is also a photographer and fashion designer. Pigozzi regularly attends The Billionaires’ Dinner (https://www.edge.org/the-billionaires-dinner), where he has been pictured with Paul Allen and Princess Olga of Greece. Other regular attendees include Jeffrey Epstein, Bill Gates, Elon Musk, Mark Zuckerberg, Jeff Bezos, Sergey Brin, John Brockman, Matt Groening (creator of The Simpsons and pervert who received a foot massage from 16 year old Virginia Giuffre), and Rupert Murdoch. Pigozzi lived about a mile away from Epstein in NYC. Pigozzi is also a good friend of Ghislaine Maxwell’s (https://www.patrickmcmullan.com/photo/1539229).
Pittman, Bob & Veronique: Robert is a co-founder of MTV and CEO of MTV Networks. He has also been CEO and/or COO of other big companies such as AOL Time Warner, Clear Channel, iHeartMedia, Six Flags Theme Parks, Quantum Media, and Century 21 Real Estate. Pittman has partied with Ghislaine Maxwell, Katie Ford (read my D-F thread for more on her), and Andre Balazs (https://pagesix.com/2007/04/28/arboreal-fashion/). Pittman has also been the Director of the One to One Foundation, a charity that works with underprivileged children (https://www.washingtonpost.com/archive/business/1998/02/15/aols-man-with-a-mission/2e4d88f1-288e-4aa5-86b4-acf68b353954/). His home address and work address are both about a mile from Epstein’s NYC mansion. Veronique is his wife.
Pittman, Sandy: Former wife of Robert Pittman (above). Sandy is an avid mountain climber. She is allegedly responsible for the death of eight people while climbing Mount Everest, as depicted in the Jake Gyllenhaal movie, Everest (https://nypost.com/2015/09/17/socialite-everest-climber-speaks-out-im-no-villain/). Sandy supposedly refused to stop climbing until they reached a top. A blizzard blasted the mountain, killing eight members of the party.
Plepler, Richard: Former Chairman and CEO of HBO. Good friend of Peggy Siegal, the well-known publicist who acted as Epstein’s plug. More on her at a later time.
Plouvier, Diane & Denis: Denis is the owner of Trousseau linen company (https://www.denisplouvier.fblank). No info found on Diane.
Podolsky, Jeffrey: Writeeditor of such publications as Tatler (again!), People Magazine, Wall Street Journal’s WSJ Magazine, and George. Lives about a ½ kilometer away from Epstein’s NYC mansion. Has been photographed with several Epstein associates (Peggy Siegal, Carol Mack, India Hicks, and others.
Polk, George: Financial analyst who served on the Council of Foreign Relations with Epstein. Polk is also a member of the World Economic Forum.
Polii, Edoardo: Powerboat champion and textile entrepreneur.
Polu, Emmanuelle: Financier at La Nef. Ghislaine Maxwell’s cousin.
Polu: Isabelle: Former head of marketing at Microsoft. Became a translator specializing in psychology. Sister of Emmanuelle and cousin of Ghislaine.
Polu, Clary: “Marketing director of Lycos and Meetic, wife of the "startup" Christophe Schaming, co-shareholder of Winamax, the online betting company co-founded by the mysterious passenger of the Lolita Express Nicole Junkermann” (http://faitsetdocuments.com/articles.html).
Porrin Ivanisevic: No info found, but the work phone number listed traces back to Globana Media Group, a printing, publishing, and multimedia group.
Porter, Pliny: Movie producer. Close friend of Julia Roberts.
Porthault, Emmanuele: No info found.
Porthault, Mr & Mrs: Marc Porthault runs the family linen business, D Porthault. Marc’s parents founded the company. Clients include Bill Gates, Woody Allen, the Mellons, and the Kennedys. Marc’s wife, Isabelle, is the head of human resources of Chanel in Europe.
Porthault, Pascal: No info found.
Porthault, Remi & Isabel: Remi is the marketing director and president of the U.S. subsidiary of D Porthault linens.
Poster, Meryl: Former President of Television at The Weinstein Company. Before that, she was Co-President of Production for Miramax Films. A phone number connected to Meryl Poster was found in Epstein co-conspirator Sarah Kellen’s phone records on October 3, 2005. The call lasted one minute (https://www.thedailybeast.com/jeffrey-epsteins-hollywood-pipeline-ran-straight-to-harvey-weinstein). Meryl is pictured here with Ghislaine Maxwell (https://www.gettyimages.com/detail/news-photo/ghislaine-maxwell-meryl-poster-and-caryn-zucker-attend-news-photo/1169681625).
Potter, Muffie: Socialite and former executive at Van Cleef & Arpels, a watch company. Married to famed plastic surgeon, Sherrell Aston. She has been photographed with Ghislaine and Peggy Siegal at various events.
Prestin, Electra: Former vice president of merchandising for Ralph Lauren and co-founder of Adam & Eve clothing company. Her father, Lewis T. Preston, was chairman of J.P. Morgan and president of the World Bank (appointed by George H.W. Bush). Her great-grandfather was newspaper publisher Joseph Pulitzer, whom the Pulitzer Prize is named after. Another great-grandfather of hers was a partner in the Standard Oil Company of John D. Rockefeller.
Prevost, Catherine: Fashion designer.
Price, Charles H. II: Banking CEO who served as U.S. Ambassador to Belgium (1981-1983) and U.S. Ambassador to the U.K. (1983-1989) during the Reagan administration. Price was also on the boards of The New York Times (1989-2002), Texaco (1989-2001), Sprint (1989-1995), British Airways (1989-1996), and other companies.
Price, Judy: Founder of Avenue, a magazine about New York City.
Princess Firyal: Jerusalem-born Jordanian princess who was once married to Prince Muhammad bin Talal. Firyal was named an UNESCO Goodwill Ambassador in 1992. Princess Firyal launched the International Hope Foundation in 1994 for the benefit of homeless and street children. Firyal holds positions with several museums (The Louvre, The Tate, MOMA, and Guggenheim), as well as positions with Columbia University, New York Public Library, United Nation Association, and International Rescue Committee.
Pritzker, Nick: Real estate and venture entrepreneur. Comes from a massively wealthy family who made their money in chewing tobacco. Former president of Hyatt Hotels. Major investor in SpaceX, Tesla, and Uber. Cousin of Thomas (below).
Pritzker, Thomas: Billionaire heir and executive chairman of Hyatt Hotels. Cousin of Governor J.B. Pritzker of Illinois. Epstein victim Virginia Giuffre named Pritzker as one of the men she had to have sex with (https://www.tampabay.com/breaking-news/jeffrey-epstein-is-gone-but-allegations-against-powerful-associates-linger-20190810/). Pritzker’s name appears twice on Epstein’s flight logs (https://archive.org/stream/EpsteinFlightLogsLolitaExpress/Jeffrey-Epstein-Flight-Logs-in-PDF-format_djvu.txt). Pritzker is listed as one of the people who has knowledge of Maxwell and Epstein’s sexual trafficking conduct and interaction with underage minors (https://www.the-sun.com/news/778758/jeffrey-epstein-enablers-named-sex-trafficking-underage-victims/). Epstein has 12 phone numbers - including an emergency contact number - and two home addresses listed under Pritzker’s name. What’s even creepier is that there is a subtitle under his name that reads “Numero Uno”. Usually when Epstein adds a subtitle under someone’s name, it indicates what company they work for or a relationship of some kind (ex: X’s husband or Y’s friend). The fact that ‘Numero Uno’ is the subtitle under Pritzker’s name is unsettling, to say the least.
Propp, Rodney: Real estate tycoon known for holding onto properties until neighborhoods gentrify.
Prunier Christy & David Doss: Doss, David & Christy Prunier: David Doss has worked as producer and/or executive producer on NBC Nightly News with Tom Brokaw, NBC Nightly News with Lester Holt, Oprah in Africa, Primetime (with Diane Sawyer), Anderson Cooper 360, and Live PD. Doss now serves as senior VP of news programming for Al Jazeera America. Christy Prunier is a former Hollywood exec and founder of the Willa brand of beauty products.
Pucci, Laudomia: Daughter of fashion icon, Emilio Pucci. Works as Image Director for the eponymous company.
Puig Marc: Chief executive and president of Puig, a fragrance and fashion company.
Puig Taria: No info found.
Puopolo, Sonia: Author and inspirational speaker. Former communications director of Haute Living, a luxury lifestyle magazine. Her mother died on 9/11 when the airplane she was on crashed into the World Trade Center. Her mother’s close friend, Hillary Clinton, read the eulogy at her funeral (https://www.dailymail.co.uk/news/article-2497916/Wedding-ring-9-11-victim-Clinton-family-friend-1-6-million-tons-Ground-Zero-rubble-provide-hope-daughter-died-hit-run-decade-later.html).
Puttnam, David: British film producer, educator, and member of the House of Lords. Puttnam was friends with Princess Diana before her passing.
Pymont, Chris: One of the top lawyers in Britain.
Quartucci, Alan: Founder of North Shore Bloodstock and North Shore Insurance, thoroughbred bloodstock companies that provide equine insurance, consulting services, racehorse management, and more.
Quinn, Topper: Investment banker who founded a couple of consulting firms.
submitted by LearningIsListening to conspiracy [link] [comments]

2020 Psychedelic Industry Insights Report

By: Nikita Alexandrov BChem, MBA - CTO, ThinkMyco
Jan 8th, 2020
2019 was a pivotal year in the psychedelic industry with US decriminalization actions, two companies receiving FDA breakthrough status for psilocybin, funding of the $16M Johns Hopkins Psychedelic Research Center, The US Defence Department starting their rumored $20M+ Focused Pharma psychedelic science program and the movement of top universities into research and clinical trials. With the explosion of the more than $100M dollars worth of investable psychedelic opportunities in Q3 2019, the collapse of high quality cannabis investments, one of the best Decembers on record and a potential $1B scale psychedelic IPO - 2020 will be the year of psychedelic investment.
The movement in the field recently is just a blip compared to what is to come, this industry has been brewing for the last few decades. Big Pharma has failed when it comes to new approaches to brain and central nervous system treatment. Due to poor understanding of mechanisms, complex clinical trials and systematic side effects, Neuro drugs have half the success rate of all Pharma projects, which caused most of the big players to reduce or cut their Neuro programs in the last decades. Recently, engagement is exploding with new clinical legislature supporting Neuro and the recent approval of 3 potentially blockbuster Neuro drugs in the last 2 years,
Q2 2019 saw a record of over $320M in investment into Neuro drug development. Interestingly enough an influential group of ultra-high net worth individuals including PayPal founder Peter Thiel funded the psychedelic holding company Atai Lifesciences which went on to fund Compass Pathways and continues to fund commercial efforts in this field. Atai Lifesciences recent movements are a familiar story of acquisition and consolidation in an emerging market which will be a common theme in the future of the psychedelic industry. In 2019 Atai Lifesciences acquired Perception Neuroscience and GABA Therapeutics for their next generation tranquillisers. Last week, Atai also acquired NeuroNasal, a non-psychedelic company creating a concussion nasal spray. In partnership with pharma, Atai's recent launch of EntheogeniX, an AI based psychedelic drug discovery platform, shows that Atai is serious about making investments into the fundamental research required to continue being an industry leader in the long-term. It is rumoured that Atai has made a number of cash investments recently, so new partnerships and acquisitions should be expected in the next months.
The collapse of investable cannabis opportunities are driving investors comfortable in stigmatised industries and binary risk to the table with big pharma, cutting edge science and huge unmet market needs to create a perfect storm of opportunity.
Highlight:
Investors seek 'mega blockbuster' drugs as neuroscience undergoes renaissance
How big is the Psychedelics Industry?
Historically, the psychedelics industry has been fragmented with around $60M worth of companies in the last 20 years, many of which were not sustainable. The current industry is around $220M+ worth of investments, dominated by the Peter Thiel backed Atia Lifesciences at $100M+ and Compass Pathways at $50M+, followed by Mind Medicine at $10M+, Fieldtrip Ventures at $10M+ and then a 10-25 early companies in the range of $2.5-10M each. The $220M+ worth of investable deals have only existed since the public formation of Compass Pathways in 2016, with the majority leaving stealth mode in 2019.
Highlight:
Transforming psychedelics into mainstream medicines
How big is the Psychedelics Market?
The psychedelics market is emerging while highly coupled to clinical/regulatory events and is split between recreational and medical psychedelic markets:
Recreational: $8-19.2B
Calculated from cannabis market and comparable usage prevalence as well as demand size economics.
Medical: $373B+
Calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.
Highlight:
Analysis of the Psilocybin Pharmaceutical Market
Who are the players?
Atai Lifesciences - German based, Global psychedelic pharma holding company formed by ultra-high net worth individuals and big pharma, $100M+
Compass Pathways - London based psychedelic giant, Atai's bet on psilocybin as an approved drug for depression, $50M+, IPO 2020
Usona Institute - A Wisconsin based non-profit powerhouse competing with Compass Pathways to approve psilocybin for depression.
Mind Medicine - Toronto based ibogaine derived addiction drug development company taking their lead candidate 18-MC through the clinical approval process, $15M+, RTO in 2020
Eleusis Benefit Corporation - New Orleans based discovery/clinical stage Psychedelic pharma company supported by industry scientists, raising $25M
FieldTrip Ventures - Toronto based, Aurora backed magic mushroom research and development company building clinical and production infrastructure, raising $12M+
ThinkMyco - Vancouver based holding company developing disruptive mushroom production technology and next generation therapeutics, raising $5M+
Gilgamesh Pharmaceuticals - Psychedelic drug discovery company affiliated with the Atai owned Perception Neuroscience and Columbia University, raising 10M+
Universal Ibogaine - Vancouver based Ibogaine clinical development company franchising the world's most advanced ibogaine clinical model, raising $10M+, RTO in 2020
PsyGen Labs - Alberta based psychedelic mass production and clinical research company with highly experienced production chemists $8M+
Entheogen Biosciences - Vancouver based company pursuing psilocybin and DMT based drug development, raising $3M, IPO in 2020
Salvation Botanicals - A Vancouver based company touting a private controlled substances site license and supporting clinical research, raising $10M+, RTO in 2020
Numinus Wellness - Vancouver based wellness company building testing as well as clinical infrastructure, partnered with Salvation, raising $5M+, RTO in 2020
Cybin Corp - Toronto based research and development company building drug development and production infrastructure as well as nutraceutical assets in legal jurisdictions, raising $3M
Emerging Players - There are a number of emerging players, around $35M+ in emerging deals in Q3 2019 which have not passed due diligence.
Clinical:
Recent data is showing psychedelics can be real mega blockbuster Neuro drugs. Johns Hopkins recent trial on Psilocybin for smoking cessation showed an 80% success rate in terminating nicotine addiction, more than double any known therapeutic approach, including nicotine replacement therapy. This is showing addiction can be treated with new mechanisms that are much more low level than replacing the drug in the receptor. Academic data unequivocally shows that Ibogaine is 95% successful in terminating acute opioid withdrawal symptoms permanently from a single dosage. Limited data from long-term Ibogaine for opioid addiction trials show 50% success rates in terminating addiction in the 6 month period with a single dosage, more than 10X higher than the generous 5% success rate of other approaches in the 6 month period. Data from leading Ibogaine providers like Universal Ibogaine show that this 50% figure can be pushed closer to 75% with proper protocols and aftercare. Clinical trials on Psilocybin for cocaine/crack addiction are ongoing at the University of Alabama at Birmingham, a top 20 medical research university. 10 patients were un-blinded for bioethics review and the unpublished data shows that 30% never touched crack again while the other 70% had a relapse or two and turned their lives around, showing a 100% success rate in changing lives with minimal cost. When this data is available publicly in the next years, tidal waves of interest will move into the field.
Highlight:
Psychedelic Clinical Research Timeline
Projections:
As a recreational market, 0.1% of the population was surveyed as using psychedelics in the last month, placing the current black market at $19.1B while as a comparable percentage of the legal cannabis market adjusted for prevalence would place it at $8B.
As a medical market, the $373B neurogenics market seems to be the addressable market. Penetration into any indication in the neurogenics market would reap vast rewards. Psilocybin is on track to compete in the depression market with two FDA breakthrough designations, a 2% penetration into the depression market would being $1.4B+ in value yearly. Ibogaine's very reasonable projected 5% penetration into the opioid dependence market in the next 10 years will bring $9.6B+ in value yearly to groups like Universal Ibogaine which are deploying clinical infrastructure, supporting clinical trials and controlling the Ibogaine supply chain. Of all of the indications in current psychedelic clinical trials, not considering crossover, they address a $400B+ market, with projected penetrations across each indication and adjustments for market factors, it is projected $16B+ of value yearly will be created from commercialisation of the current late stage clinical trials which are in progress.
Highlight:
Johns Hopkins Psilocybin for Smoking Cessation Data
Challenges:
Regulatory Challenges:
While nearly 100 cities are creating legislation to decriminalize psychedelics and multiple US jurisdictions have passed decriminalization, federal changes will be required to open legal markets to the full potential. While investing in the binary risk of regulatory changes is standard in the junior markets, current regulatory controls are preventing early revenues. Many Canadian companies building production and distribution infrastructure offshore in jurisdictions such as Jamaica are operating in a legal grey area. While it is legal in Jamaica, any benefit or advantage given to a Canadian company could be considered a proceed of crime including IP development, capital repatriation and validation of technology offshore. Section 56 exemptions from Health Canada are required for Canadian companies working with psychedelics offshore and companies which are raising investment dollars without a secured Section 56 exemption may be incurring legal risk.
Cardiac Liability:
The unspoken elephant in the room of psychedelic derived pharmaceutical acceptance is not regulation, for example Ketamine is a scheduled drug which was recently approved for the general market. The problem is actually the liability of bringing a seratonergic based drug to the market like Psilocybin, DMT and LSD. The crippling withdrawal of blockbuster drug Fen-Phen and issues with other drugs like Imitrex due to seratonin agonist effects on the heart have scared the FDA into a position that any seratonergic drug will require extreme cooperation and diligence and will absolutely incur additional clinical and monitoring costs over other drugs. Psilocybin while technically hitting the 5ht2b receptor which causes cardiac side effects, does not have a high enough affinity to be a deal-breaker, meanwhile LSD having a very high affinity will cause large barriers for groups attempting to bring microdosed LSD to the market. Ibogaine suffers from cardiac liability due to an entirely different mechanism and unlike Psilocybin or LSD, adverse events have been reported. While Methadone and other standards of care also have the same long-QT cardiac liability at much higher rates and significantly higher mortality rates , Ibogaine clinical models must pre-screen patients for existing heart defects before procedures to guarantee no adverse side effects.
Banking/Insurance/Exchange Issues:
Legitimate psychedelic derived drug development companies have already had bank accounts halted at multiple banks for involvement in this industry and moving forward similar challenges faced by the cannabis industry should be expected. Exchanges and public offerings will have logistic challenges with this industry and minor friction has already been seen in the listing process. DNO insurance and other underwriting will be required to list in large markets and to date no psychedelic company has been underwritten, although underwriters and leading insurance brokers are actively exploring his industry.
Reimbursement:
The real whale will be insurance and single payer reimbursement of psychedelic derived pharmaceuticals on the market, allowing for global market uptake. Health systems have traditionally been decades behind the state of the art as seen in the point of care and home diagnostic device market, a market which could keep people healthy at minimal cost but has been crippled by lack of reimbursement.
Supply Chain Commoditization:
The production and control of psychedelic supply chains which is the familiar play of the cannabis industry will be a race to the bottom with magic mushrooms and other psychedelics. Production models are competing with a much more fluid black market and are being cannibalized by low cost home production and wildcrafting of psilocybin mushrooms. The LSD or ergoloid supply chain is highly monopolized, with the majority of the worlds ergoloids being produced in a single location. Companies competing in the production and supply chain space will face heavy price pressure and a highly coupled global regulatory system. The single outlier is Ibogaine, with a current global use estimated around 90kg, expected to reach 280kg in the next few years, this is a commodity whose price will drive through the roof. Large ibogaine producers have stopped production and natural sources are not commercially viable, with an Iboga plant producing maybe a single dose on the 10 year period, the move of Ibogaine to endangered status in 2019 and no synthetic GMP producers - the Ibogaine market is legal in the majority of the world and exploding while highly underserved and fragmented.
Delivery System Challenges:
A number of recent psychedelic deals are built around new drug delivery systems for psychedelics entering the recreational market to build expertise and infrastructure ready to move into the pharmaceutical market. Many of these technological approaches will not translate from the recreational market to the pharmaceutical market such as CBD/psychedelic compositions, natural product compositions as well as vaporizer and inhaler based delivery systems. While 20%+ of all new FDA drug entities are derived from natural products, natural product mixtures containing many products and a controlled substance have never and will never be FDA approved due to the regulatory system. Companies developing Psilocybin/CBD combinations and related therapeutics for the recreational market should understand that unlike the cannabis market, recreational approaches will not translate directly to medical approaches.
Opportunities:
Syndicated Investments:
One of the largest opportunities in any emerging market is syndicated investment, a 2002 analysis of 584 venture backed exits showed that syndicated investments produced double the rate of return of non-syndicated investments. Psychedelic research and development companies require standardized infrastructure that can be leveraged across a number of players. The big players entering the industry are more interested in empire building, requiring massive consolidations of commercial efforts which can be facilitated by syndicated investment groups. Companies like ThinkMyco, Entheogen Biosciences and Cybin Corporation which focus on technology development, IP Portfolios and early stage drug discovery will benefit the most from syndicated investment and collaboration. A Harvard Business School review of Pharma discovery programs statistically compared drug discovery programs to weapons research programs and found in these high reward/low incremental cost programs the optimal path is to run parallel programs, with an average Pharma drug discovery program having 16 parallel programs, 10 core and 6 low budget/high risk. At the current moment, around 5-10 psychedelic investment funds are forming in the range of $10-50M each, including the Cannacord Genuity backed Entheos and the $20M psychedelic quant fund Tabula Rasa Ventures.
IP Portfolio Development:
IP development is the highest value for dollar on the investment value chain and the psychedelic industry will be a totally IP driven industry. The most valuable patent portfolios will include new psychedelic compositions and therapeutic mechanisms, which require significant investments into fundamental R+D, while less competitive portfolios will include delivery system/psychedelic combinations.A recent review of patents related to psychedelics shows many hundreds of patents for psychedelic derived therapeutics with only a small cross-section being commercially competitive. DemeRX, the $40M+ Ibogaine research company holds 65+ patents in the ibogaine therapeutic area. While DemeRX filed for bankruptcy and their research and development assets were liquidated, it is rumored they have been injected with enough capital to come back to the party - this is a dark horse to keep an eye out for.
Mushroom/Protein Connection:
The real opportunity in magic mushroom production models is flying under the radar: protein production. Mushrooms are one of the highest quality sources of nutrition and protein, if you took a vitamin C supplement you can live exclusively off mushrooms. Dried mushrooms have basically the same protein percentage as beef and in terms of grams of protein per acre per year are 100 fold higher producers and much more sustainable than traditional agricultural practices. Companies in this space which invest into real R+D for lower cost mushroom production will get a lift from the $1.8+ trillion dollar protein market. A recent review of mid-sized mushroom farms shows that 50%+ of the cost of mushroom production is due to labor and technical inefficiencies. If energy, labor and materials cost drivers can be reduced, and the cost of growing a pound of mushrooms can drop from around $2 to around $0.75 through automation, mushroom protein becomes significantly more commercially competitive than many of the industry leaders in plant based protein like pea protein. If energy cost reductions can drop the cost even further, mushrooms will become a disruptive food source. Psychedelic companies building mushroom production infrastructure will be well served to remember that by investing in automation, new technology and new growing systems the price of mushroom based protein production can make it more competitive than any other food source. The largest food security report in history was released Q2 2019 and showed that without subsidies a hamburger would cost more than 30$ and the meat industry will economically collapse by 2040, the protein game is looking more and more attractive as a hedge against the regulatory risk of magic mushroom production.
China:
China is one of the most advanced markets in terms of size and pharma spending, as well as venture investment. Traditionally the Asian cultures had no interest in marginalized and politically tense areas such as drug medicalization but the movement into CBD and China's rabid interest in plant medicines may create a large influx of Asian capital moving into psychedelics. This industry shifting action will be leveraged by education and the court of public opinion. A dialog must be created showing psilocybin as a plant medicine and not a drug of abuse. Interestingly enough, Chinese firms have very recently started producing magic mushrooms industrially and importing them into the Canadian market where they are sold into the black market over-the-counter in some Canadian herbalist stores.
Ibogaine:
Ibogaine is the only psychedelic model which will not be very quickly commoditized. Ibogaine as a solution to the opioid problem is a disruptive technology, with the rise of fentanyl and fentanyl analogs like carfentanil dominating global supply chains, Buprenorphine, the preferred standard of care is no longer effective and produces a life threatening condition called Precipitated Withdrawal. This is due to the aggressive affinity of fentanyl to receptors, the lack of tolerance ceiling and the little understood metabolism of next-generation fentanyl analogues, dramatically compounding a problem already at pandemic levels. Ibogaine supply chains have collapsed at the same time that demand is growing exponentially, the firm which dominates the current global ibogaine supply chain will reap around $1.4M/mo profit serving the current global demand. One of the largest African Ibogaine brokers has seen a 30x increase in sales from 2017 to 2019. With Universal Ibogaine taking Ibogaine through the Canadian clinical process and the grassroots support from Health Canada, Ibogaine will be the first psychedelic approach available to consumers. While Ibogaine is a scheduled drug in the US and some European jurisdictions, it is not scheduled in Canada and the majority of the global market. Multiple Ibogaine documentaries are in filming, including actors such as Johnny Depp, as this is an education driven industry, we should expect exponential growth to accelerate in 2020.
Support Industries:
Industries supporting the growth of psychedelics will be a large part of the future landscape as was seen in the cannabis sector. A psychedelic business support network including education, conferences, business analysis and financing have already cropped up commercially. In Q3 2019 the renowned Cambridge House International Extraordinary Future conference created a panel for psychedelic opportunities. Two weeks before the conference there was a frantic rush and the majority of relevant psychedelic players were represented last minute in the panel discussion including: Compass Pathways, FieldTrip Ventures, Mind Medicine, Johns Hopkins, Dennis McKenna and ThinkMyco. Multiple psychedelic investment funds are forming alongside of industry press, consulting groups and other support interests. In Q3 2019, Dr. Matthew Thompson of Johns Hopkins and Dr. Charles Nichols of LSU/Eleusis Benefit Corporation helped organize the inaugural conference for the new journal called International Society for Research on Psychedelics in its home of New Orleans. Over 100 international scientists from top universities were represented, with the conference having to turn down many late registrations. Dr. Rolland Griffiths, head of the Johns Hopkins Psychedelic Research Center said "This was the best scientific conference I have been to in my entire career.".
Sub-perceptual dosing:
Microdosing was popularized by Silicon Valley, catalyzing the resurgence of the psychedelic industry but microdosing is a protocol built on unsound fundamentals. Research shows that the therapeutic effects of psychedelics are highly dose dependant, higher doses lead to better therapeutic effects. The microdosing supply chain model has excellent returns, with a pound of mushrooms costing less than 5$/lb to produce which provides around 1200X microdoses. When dosages increase past the perceptual threshold, the potential for adverse events such as bad trips exponentially increases. The ideal dosage seems to be just under perceptual threshold where you can still go about your day, but much higher than a microdose. This is industry standard with seratonergic pharmaceuticals, an example being the diet drug Belvique, which is closely related to psilocybin, dosed at the perceptual threshold for maximum effectiveness. Belvique can cause psilocybin like hallucinations if 4 tablets are taken as it is a seratonergic drug. High doses of psilocybin require a clinical infrastructure and in-patient experience, dramatically increasing costs and logistics overheads. Sub-perceptual dosed pharmaceuticals will be available for out-patient and take home treatment and in many cases may be as effective as full blown psychedelic experiences. Mind Medicine, ThinkMyco and Eleusis Benefit Corporation are leading the charge in sub-perceptual therapeutics.
Next Generation Drug Development:
Mind Medicine is taking the approach of engineering the hallucinations out of the therapeutic experience by removing parts of the molecule and are moving their drug, 18-MC through the clinical process. This is the ultimate high risk/high reward play in the psychedelic industry. 18-MC is modified which also changes a variety of important receptor binding effects. The modified receptors include the receptors responsible for neural growth factor release, cognitive effects, cardiac effects and the opioid system coupled NMDA receptor system. Since there is no data on the human use of 18-MC in opioid addicts, significant capital must be deployed before it is even known if 18-MC is as efficient as the parent molecule Ibogaine for treating opioid addiction, the ability to treat addiction in an out-patient setting with no cardiac toxicity - 18-MC will be the megablockbuster all investors in the neurogenic space are waiting for. ThinkMyco, Gilgamesh Pharmaceuticals, Mind Medicine and Eleusis Benefit Corporation are leading the field in next generation drug development.
Lateral Drug Development:
While psychedelics address a $373B neurogenics market, companies such as Eleusis Benefit Corporation are showing they can address other unmet clinical needs such as chronic inflammatory disease. Eleusis is developing new psychedelic compounds for the treatment of inflammation, specifically within ophthalmology, and has recently published Phase I trial results revealing the safety and tolerability of low dose LSD in healthy older adults, with the intention of evaluating low dose LSD as a disease modifying therapy in Alzheimer's disease. Eleusis Benefit Corporation looks poised to cannibalize the $3B steroid therapeutic market. Not yet published research is showing Ibogaines potential as a therapeutic to treat sleep disorders. Johns Hopkins is currently reviewing the application of psychedelics in pulling patients from comas and vegetative states. The original pre-Mind Medicine clinical trials on the Ibogaine derivative 18-MC showed promise in treating Leishmania infection. BOL148, an inactive form of LSD, originally the placebo in human clinical LSD research, was found to in some cases to permanently terminate cluster headaches after a few doses and is being publicly demanded from the cluster headache community. These are the earliest days of understanding the application of psychedelic derived chemistry as new therapeutic approaches.
Public Health Engagement:
Looking at recently released data representing North American, working class adults, methamphetamine and fentanyl use is growing enormously and consistently. Linear regression of growth rates over the last 5 years projects a 380%+ increase in Fentanyl usage the next 15 years, with Methamphetamine projected at a 475%+ increase. This is concerning as there are more than a million high quality data points over 5 years and an R2 value of 90%+ which paints of picture of statistical certainty. This shows that the opioid crisis has moved from a lift caused by supply side drivers to an organically growing demand side driven pandemic, fueled secondarily by histories cheapest and most available synthetic drugs. With Johnson and Johnson settling with two counties in Ohio, projections have placed the total at $100B+ in fines for the opioid crisis in the next few years. State jurisdictions will shortly receive an enormous amount of cash that will be legally obligated to flow into anti-addiction spending. Due to poor outcomes and non-scalable approaches around advanced public health programs, there will be a flurry of legislature to address how to spend the $100B+ anti-addiction warchest. Players like Universal Ibogaine who have proven clinical models, can deploy infrastructure and guarantee statistically better outcomes will receive unprecedented amounts of non-dilutive government funding and will be the first to benefit from Decriminalization/Medicalization in the North American market. Players that can come to the table now at the state level and propose medicalization legislature as well as profitable clinical infrastructure with proven outcomes, could monopolize the entire US market. FieldTrip Ventures is developing Psilocybin clinical infrastructure while Universal Ibogaine is deploying proven clinical infrastructure already developed and proven by Clear Sky Recovery, the leading Ibogaine clinical experts with thousands of successful detox procedures and no critical adverse events.
Closing:
Like any emerging industry, there are challenges and growing pains but the blue-sky upside is unparalleled. "Black swan events are characterised by their extreme rarity, their severe impact, and the practice of explaining widespread failure to predict them as simple folly in hindsight." Due to changes in public opinion, a mental health and addiction pandemic as well as enormous movements of liquid cash, this sector is poised to explode in 2020.
submitted by mindovermatterlondon to investing [link] [comments]

2020 Psychedelic Industry Insights Report - ThinkMyco

2020 Psychedelic Industry Insights Report
By: Nikita Alexandrov BChem, MBA - CTO, ThinkMyco
[email protected]
Jan 8th, 2020
2019 was a pivotal year in the psychedelic industry with US decriminalization actions, two companies receiving FDA breakthrough status for psilocybin, funding of the $16M Johns Hopkins Psychedelic Research Center, The US Defence Department starting their rumored $20M+ Focused Pharma psychedelic science program and the movement of top universities into research and clinical trials. With the explosion of the more than $100M dollars worth of investable psychedelic opportunities in Q3 2019, the collapse of high quality cannabis investments, one of the best decembers on record and a potential $1B scale psychedelic IPO - 2020 will be the year of psychedelic investment.
The movement in the field recently is just a blip compared to what is to come, this industry has been brewing for the last few decades. Big Pharma has failed when it comes to new approaches to brain and central nervous system treatment. Neuro drugs have half the success rate of all Pharma projects, which caused most of the big players to liquidate their neuro programs in the last decade. Recently, engagement is exploding with new clinical legislature supporting neuro, the recent approval of 3 potentially blockbuster neuro drugs in the last 2 years, Q2 2019 saw a record of over $320M in investment into neuro drug development. Interestingly enough an influential group of ultra-high net worth individuals to funded the psychedelic holding company Atai Lifesciences which went on to fund Compass Pathways and continues to fund commercial efforts in this field. Atai Lifesciences recent movements are a familiar story of acquisition and consolidation in an emerging market which will be a common theme in the future of the psychedelic industry. The collapse of investable cannabis opportunities are driving investors comfortable in stigmatized industries and binary risk to the table with big pharma, cutting edge science and huge unmet market needs to create a perfect storm of opportunity.
Highlight:
Investors seek 'mega blockbuster' drugs as neuroscience undergoes renaissance
How big is the Psychedelic Industry?
Historically, the psychedelic industry has been fragmented with around $60M worth of companies in the last 20 years, many of which were not sustainable. The current industry is around $300M worth of investments, dominated by the Peter Thiel backed Atia Lifesciences at $100M+ and Compass Pathways at $50M+, followed by Mind Medicine at $10M+, Fieldtrip Ventures at $10M+ and then a 10-15 early companies in the range of $2.5-10M each. The $300M worth of investable deals have only existed since the public formation of Compass Pathways in 2016, with the majority leaving stealth mode in 2019.
Highlight:
Transforming psychedelics into mainstream medicines
How big is the Psychedelic Market?
The psychedelic market is emerging while highly coupled to clinical/regulatory events and is split between recreational and medical psychedelic markets:
Recreational: $8-19.2B
Calculated from cannabis market and comparable usage prevalence as well as demand size economics.
Medical: $373B
Calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.
Highlight: Analysis of the Psilocybin Pharmaceutical Market
Who are the players?
Atai Lifesciences - German based, Global psychedelic pharma holding company formed by ultra-high net worth individuals and big pharma, $150M+
Compass Pathways - London based psychedelic giant, Atai's bet on psilocybin as an approved drug for depression, $50M+, IPO 2020
Usona Institute - A Wisconsin based non-profit powerhouse competing with Compass Pathways to approve psilocybin for depression.
Mind Medicine - Toronto based ibogaine derived addiction drug development company taking their lead candidate 18-MC through the clinical approval process, raising $15M, RTO in 2020
Eleusis Benefit Corporation - New Orleans based discovery/clinical stage Psychedelic pharma company supported by industry scientists, raising $25M
FieldTrip Ventures - Toronto based, Aurora backed magic mushroom research and development company building clinical and production infrastructure, raising $10M+
ThinkMyco - Vancouver based holding company developing disruptive mushroom production technology and next generation therapeutics, raising $5M+
Gilgamesh - Psychedelic drug discovery company affiliated with the Atai owned Perception Neuroscience and Columbia University, raising 10M+
Universal Ibogaine - Vancouver based Ibogaine clinical development company franchising the world's most advanced ibogaine clinical model, raising $10M+, RTO in 2020
PsyGen - Alberta based psychedelic mass production and clinical research company with highly experienced production chemists $5M+
Entheogen Biosciences - Vancouver based company pursuing psilocybin and DMT based drug development, raising $3M, IPO in 2020
Salvation Botanicals - A Vancouver based company touting a private controlled substances site license and supporting clinical research, raising $10M+, RTO in 2020 Numinus Wellness - Vancouver based wellness company building testing as well as clinical infrastructure, partnered with Salvation, raising $5M+, RTO in 2020
Cybin Corp - Toronto based research and development company building drug development and production infrastructure as well as nutraceutical assets in legal jurisdictions, raising $3M
Emerging Players - There are a number of emerging players, around $25M+ in emerging deals in Q3 2019 which have not passed due diligence.

Clinical:
Recent data is showing psychedelics can be real mega blockbuster neuro drugs. Johns Hopkins recent trial on Psilocybin for smoking cessation showed an 80% success rate in terminating nicotine addiction, more than double any known therapeutic approach, including nicotine replacement therapy. Academic data shows that Ibogaine is 95% successful in terminating acute opioid withdrawal/addiction. Limited data from Ibogaine for opioid addiction trials show 50% success rates in terminating addiction, more than 10X higher than the generous 5% success rate of other approaches. Data from leading Ibogaine providers like Universal Ibogaine show that this 50% figure can be pushed closer to 75% with proper protocols and aftercare. Clinical trials on Psilocybin for cocaine/crack addiction are ongoing at the University of Alabama at Birmingham, a top 20 medical research university. 10 patients were un-blinded for bioethics review and the unpublished data shows that 30% never touched cocaine again while the other 70% had a relapse or two and turned their lives around, showing a 100% success rate in changing lives with minimal cost. When this data is available publicly in the next years, tidal waves of interest will move into the field.
Highlight:
Psychedelic Clinical Research Timeline
Projections:
As a recreational market, 0.1% of the population was surveyed as using psychedelics in the last month, placing the current black market at $19.1B while as a comparable percentage of the legal cannabis market adjusted for prevalence would place it at $8B.
As a medical market, the $373B neurogenics market seems to be the addressable market. Penetration into any indication in the neurogenics market would reap vast rewards, Psilocybin is on track to compete in the depression market with two FDA breakthrough designations, a 2% penetration into the depression market would being $1.4B in value. Ibogaines very reasonable projected 4% penetration into the opioid dependence market will bring $9.6B in value yearly to groups like Universal Ibogaine which are deploying clinical infrastructure, supporting clinical trials and controlling the Ibogaine supply chain. Of all of the indications in current psychedelic clinical trials, not considering crossover, they address a $400B+ market, with projected penetrations across each indication and adjustments for market factors, it is projected $16B+ of value yearly will be created from commercialization of current late stage clinical trials.
Highlight: Johns Hopkins Psilocybin for Smoking Cessation Data
Challenges:
Regulatory Challenges:
While nearly 100 cities are creating legislation to decriminalize psychedelics and multiple US jurisdictions have passed decriminalization, federal changes will be required to open legal markets to the full potential. While investing in the binary risk of regulatory changes is standard in the junior markets, current regulatory controls are preventing early revenues. Many Canadian companies building production and distribution infrastructure offshore in jurisdictions such as Jamaica are operating in a legal grey area. While it is legal in Jamaica, any benefit or advantage given to a Canadian company could be considered a proceed of crime including IP development, capital repatriation and validation of technology offshore. Section 56 exemptions from Health Canada are required for Canadian companies working with psychedelics offshore and companies which are raising investment dollars without a secured Section 56 exemption may be incurring legal risk.
Cardiac Liability:
The unspoken elephant in the room of psychedelic derived pharmaceutical acceptance is not regulation, for example Ketamine is a scheduled drug which was recently approved. The problem is actually the liability of bringing a seratonergic based drug to the market like Psilocybin, DMT and LSD. The crippling withdrawal of blockbuster drugs Fen-Phen and issues with other drugs like Imitrex due to seratonin agonist effects on the heart have scared the FDA into a position that any seratonergic drug will require extreme cooperation and diligence and will absolutely incur additional clinical and monitoring costs over other drugs. Psilocybin while technically hitting the 5ht2b receptor which causes cardiac side effects, does not have a high enough affinity to be a deal-breaker, meanwhile LSD having a very high affinity will cause large barriers for groups attempting to bring microdosed LSD to the market. Ibogaine suffers from cardiac liability due to an entirely different mechanism and unlike Psilocybin or LSD, adverse events have been reported. While Methadone and other standards of care also have the same long-QT cardiac liability at much higher rates and significantly higher mortality rates , Ibogaine clinical models must pre-screen patients for existing heart defects before procedures to guarantee no adverse side effects.
Banking/Insurance/Exchange Issues:
Legitimate psychedelic derived drug development companies have already had bank accounts halted at multiple banks for involvement in this industry and moving forward similar challenges faced by the cannabis industry should be expected. Exchanges and public offerings will have logistic challenges with this industry and minor friction has already been seen in the listing process. DNO insurance and other underwriting will be required to list in large markets and to date no psychedelic company has been underwritten, although underwriters and leading insurance brokers are actively exploring his industry.
Reimbursement:
The real whale will be insurance and single payer reimbursement of psychedelic derived pharmaceuticals on the market, allowing for global market uptake. Health systems have traditionally been decades behind the state of the art as seen in the point of care and home diagnostic device market, a market which could keep people healthy at minimal cost but has been crippled by lack of reimbursement.
Supply Chain Commoditization:
The production and control of psychedelic supply chains which is the familiar play of the cannabis industry will be a race to the bottom with magic mushrooms and other psychedelics. Production models are competing with a much more fluid black market and are being cannibalized by low cost home production and wildcrafting of psilocybin mushrooms. The LSD or ergoloid supply chain is highly monopolized, with the majority of the worlds ergoloids being produced in a single location.
Companies competing in the production and supply chain space will face heavy price pressure and a highly coupled global regulatory system. The single outlier is Ibogaine, with a current global use estimated around 90kg, expected to reach 280kg in the next two years, this is a commodity whose price will drive through the roof. Large ibogaine producers have stopped production and natural sources are not commercially viable, with an Iboga plant producing maybe a single dose on the 10 year period, the move of ibogaine to endangered status in 2019 and no synthetic GMP producers - the ibogaine market is legal in the majority of the world and exploding while highly underserved and fragmented.
Delivery System Challenges:
A number of recent psychedelic deals are built around new drug delivery systems for psychedelics entering the recreational market to build expertise and infrastructure ready to move into the pharmaceutical market. Many of these technological approaches will not translate from the recreational market to the pharmaceutical market such as CBD/psychedelic compositions, natural product compositions as well as vaporizer and inhaler based delivery systems. While 20%+ of all new FDA drug entities are derived from natural products, natural product mixtures containing many products and a controlled substance have never and will never be FDA approved due to the regulatory system. Companies developing Psilocybin/CBD combinations and related therapeutics for the recreational market should understand that unlike the cannabis market, recreational approaches will not translate directly to medical approaches.
Opportunities:
Syndicated Investments:
One of the largest opportunities in any emerging market is syndicated investment, a 2002 analysis of 584 venture backed exits showed that syndicated investments produced double the rate of return of non-syndicated investments. Psychedelic research and development companies require standardized infrastructure that can be leveraged across a number of players. The big players entering the industry are more interested in empire building, requiring massive consolidations of commercial efforts which can be facilitated by syndicated investment groups. Companies like ThinkMyco, Entheogen Biosciences and Cybin Corporation which focus on technology development, IP Portfolios and early stage drug discovery will benefit the most from syndicated investment and collaboration. A Harvard Business School review of Pharma discovery programs statistically compared drug discovery programs to weapons research programs and found in these high reward/low incremental cost programs the optimal path is to run parallel programs, with an average Pharma drug discovery program having 16 parallel programs, 10 core and 6 low budget/high risk.
IP Portfolio Development:
IP development is the highest value for dollar on the investment value chain and the psychedelic industry will be a totally IP driven industry. The most valuable patent portfolios will include new psychedelic compositions and therapeutic mechanisms, which require significant investments into fundamental R+D, while less competitive portfolios will include delivery system/psychedelic combinations.
A recent review of patents related to psychedelics shows many hundreds of patents for psychedelic derived therapeutics with only a small cross-section being commercially competitive. DemeRX, the $40M+ Ibogaine research company holds 65+ patents in the ibogaine therapeutic area. While DemeRX filed for bankruptcy and their research and development assets were liquidated, it is rumored they have been injected with enough capital to come back to the party - this is a dark horse to keep an eye out for.
Mushroom/Protein Connection:
The real opportunity in magic mushroom production models is flying under the radar: protein production. Mushrooms are one of the highest quality sources of nutrition and protein, if you took a vitamin C supplement you can live exclusively off mushrooms. Dried mushrooms have basically the same protein percentage as beef and in terms of grams of protein per acre per year are 100 fold higher producers and much more sustainable than traditional agricultural practices. Companies in this space which invest into real R+D for lower cost mushroom production will get a lift from the $1.8 trillion dollar protein market. A recent review of mid-sized mushroom farms shows that 50%+ of the cost of mushroom production is due to labor and technical inefficiencies. If energy, labor and materials cost drivers can be reduced, and the cost of growing a pound of mushrooms can drop from around $2 to around $1.20 through automation, mushroom protein becomes significantly more competitive than many of the industry leaders in plant based protein like pea protein. If energy cost reductions can drop the cost even further, mushrooms will become a disruptive food source. Psychedelic companies building mushroom production infrastructure will be well served to remember that by investing in automation, new technology and new growing systems the price of mushroom based protein production can make it more competitive than any other food source. The largest food security report in history was released Q2 2019 and showed that without subsidies a hamburger would cost more than 30$ and the meat industry will economically collapse by 2040, the protein game is looking more and more attractive as a hedge against the regulatory risk of magic mushroom production.
China:
China is one of the most advanced markets in terms of size and pharma spending, as well as venture investment. Traditionally the Asian cultures had no interest in marginalized and politically tense areas such as drug medicalization but the movement into CBD and China's rabid interest in plant medicines may create a large influx of Asian capital moving into psychedelics. This industry shifting action will be leveraged by education and the court of public opinion. A dialog must be created showing psilocybin as a plant medicine and not a drug of abuse. Interestingly enough, Chinese firms have very recently started producing magic mushrooms industrially and importing them into the Canadian market where they are sold into the black market over-the-counter in some Canadian herbalist stores.
Ibogaine:
Ibogaine is the only psychedelic model which will not be very quickly commoditized. Ibogaine as a solution to the opioid problem is a disruptive technology, with the rise of fentanyl and fentanyl analogs like carfentanil dominating global supply chains, Buprenorphine, the preferred standard of care is no longer effective. This is due to the aggressive affinity of fentanyl to receptors, the lack of tolerance ceiling and the little understood metabolism of next-generation fentanyl analogues, dramatically compounding a problem already at pandemic levels. Ibogaine supply chains have collapsed at the same time that demand is growing exponentially, the firm which dominates the current global ibogaine supply chain will reap around $1.4M/mo profit serving the current global demand. One of the largest African Ibogaine brokers has seen a 30x increase in sales from 2017 to 2019. With Universal Ibogaine taking Ibogaine through the Canadian clinical process and the grassroots support from Health Canada, Ibogaine will be the first psychedelic approach available to consumers. While Ibogaine is a scheduled drug in the US and some European jurisdictions, it is not scheduled in Canada and the majority of the global market. Multiple Ibogaine documentaries are in filming, including actors such as Johnny Depp, as this is an education driven industry, we should expect exponential growth to accelerate in 2020.
Support Industries:
Industries supporting the growth of psychedelics will be a large part of the future landscape as was seen in the cannabis sector. A psychedelic business support network including education, conferences, business analysis and financing have already cropped up commercially. In Q3 2019 the renowned Cambridge House International Extraordinary Future conference created a panel for psychedelic opportunities. Two weeks before the conference there was a frantic rush and the majority of relevant psychedelic players were represented last minute in the panel discussion including: Compass Pathways, FieldTrip Ventures, Mind Medicine, Johns Hopkins, Dennis McKenna and ThinkMyco. Multiple psychedelic investment funds are forming alongside of industry press, consulting groups and other support interests. In Q3 2019, Dr. Matthew Thompson of Johns Hopkins and Dr. Charles Nichols of LSU/Eleusis Benefit Corporation helped organize the inaugural conference for the new journal called International Society for Research on Psychedelics in its home of New Orleans. Over 100 international scientists from top universities were represented, with the conference having to turn down many late registrations. Dr. Rolland Griffiths, head of the Johns Hopkins Psychedelic Research Center said "This was the best scientific conference I have been to in my entire career.".
Sub-perceptual dosing:
Microdosing was popularized by Silicon Valley, catalyzing the resurgence of the psychedelic industry but microdosing is a protocol built on unsound fundamentals. Research shows that the therapeutic effects of psychedelics are highly dose dependant, higher doses lead to better therapeutic effects. The microdosing supply chain model has excellent returns, with a pound of mushrooms costing less than 5$/lb to produce which provides around 1200x microdoses. When dosages increase past the perception threshold, the potential for adverse events such as bad trips exponentially increases. The ideal dosage seems to be just under perceptual threshold where you can still go about your day, but much higher than a microdose. This is industry standard with seratonergic pharmaceuticals, an example being the diet drug Belvique, which is closely related to psilocybin, dosed at the perceptual threshold for maximum effectiveness. Belvique can cause psilocybin like hallucinations if 4 tablets are taken as it is a seratonergic drug. High doses of psilocybin require a clinical infrastructure and in-patient experience, dramatically increasing costs and logistics overheads. Sub-perceptual dosed pharmaceuticals will be available for out-patient and take home treatment and in many cases may be as effective as full blown psychedelic experiences. Mind Medicine, ThinkMyco and Eleusis Benefit Corporation are leading the charge in sub-perceptual therapeutics.
Next Generation Drug Development:
Mind Medicine is taking the approach of engineering the hallucinations out of the therapeutic experience by removing parts of the molecule and are moving their drug, 18-MC through the clinical process. This is the ultimate high risk/high reward play in the psychedelic industry. 18-MC is modified which also changes a variety of important receptor binding effects. The modified receptors include the receptors responsible for growth factor release, cognitive effects, cardiac effects and the opioid system coupled NMDA receptors. Since there is no data on the human use of 18-MC in opioid addicts, significant capital must be deployed before it is even known if 18-MC is as efficient as the parent molecule Ibogaine for treating opioid addiction, the ability to treat addiction in an out-patient setting with no cardiac toxicity - 18-MC will be the megablockbuster all investors in the neurogenic space are waiting for. ThinkMyco, Gilgamesh, Mind Medicine and Eleusis Benefit Corporation are leading the field in next generation drug development.
Lateral Drug Development:
While psychedelics address a $373B neurogenics market, companies such as Eleusis Benefit Corporation are showing they can address other unmet clinical needs such as chronic inflammatory disease. Eleusis is developing new psychedelic compounds for the treatment of inflammation, specifically within ophthalmology, and has recently published Phase I trial results revealing the safety and tolerability of low dose LSD in healthy older adults, with the intention of evaluating low dose LSD as a disease modifying therapy in Alzheimer's disease. Eleusis Benefit Corporation looks poised to cannibalize the $3B steroid therapeutic market. Not yet published research is showing Ibogaines potential as a therapeutic to treat sleep disorders. Johns Hopkins is currently reviewing the application of psychedelics in pulling patients from comas and vegetative states. The original pre-Mind Medicine clinical trials on the Ibogaine derivative 18-MC showed promise in treating Leishmania infection. BOL148, an inactive form of LSD, originally the placebo in human clinical LSD research, was found to in some cases to permanently terminate cluster headaches after a few doses and is being publicly demanded from the cluster headache community. These are the earliest days of understanding the application of psychedelic derived chemistry as new therapeutic approaches.
Public Health Engagement:
Looking at recently released data representing North American, working class adults, methamphetamine and fentanyl use is growing enormously and consistently. Linear regression of growth rates over the last 5 years projects a 380%+ increase in Fentanyl usage the next 15 years, with Methamphetamine projected at a 475%+ increase. This is concerning as there are more than a million high quality data points over 5 years and an R2 value of 90%+ which paints of picture of statistical certainty. This shows that the opioid crisis has moved from a lift caused by supply side drivers to an organically growing demand side driven pandemic fueled secondarily by histories cheapest and most available synthetic drugs. With $100B+ in fines projected for the opioid crisis in the next few years, state jurisdictions will shortly receive an enormous amount of cash that will be legally obligated to flow into anti-addiction spending. Due to poor outcomes and non-scalable approaches around advanced public health programs, there will be a flurry of legislature to address how to spend the $100B+ anti-addiction warchest. Players like Universal Ibogaine who have proven clinical models, can deploy infrastructure and guarantee statistically better outcomes will receive unprecedented amounts of non-dilutive government funding and will be the first to benefit from Decriminalization/Medicalization in the North American market. Players that can come to the table now at the state level and propose medicalization legislature as well as profitable clinical infrastructure with proven outcomes, could monopolize the entire US market. FieldTrip Ventures is developing Psilocybin clinical infrastructure while Universal Ibogaine is deploying proven clinical infrastructure already developed and proven by Clear Sky Recovery, the leading Ibogaine clinical experts with thousands of successful detox procedures and no critical adverse events.
Closing:
Like any emerging industry, there are challenges and growing pains but the blue-sky upside is unparalleled. "Black swan events are characterized by their extreme rarity, their severe impact, and the practice of explaining widespread failure to predict them as simple folly in hindsight." Due to changes in public opinion, a mental health and addiction pandemic as well as enormous movements of liquid cash, this sector is poised to explode in 2020.
Additional information requests: [[email protected]](mailto:[email protected])
submitted by mindovermatterlondon to shroomstocks [link] [comments]

2020 Psychedelic Industry Insights Report

2020 Psychedelic Industry Insights Report
By: Nikita Alexandrov BChem, MBA - CTO, ThinkMyco
[[email protected]](mailto:[email protected])
Jan 8th, 2020
2019 was a pivotal year in the psychedelic industry with US decriminalization actions, two companies receiving FDA breakthrough status for psilocybin, funding of the $16M Johns Hopkins Psychedelic Research Center, The US Defence Department starting their rumored $20M+ Focused Pharma psychedelic science program and the movement of top universities into research and clinical trials. With the explosion of the more than $100M dollars worth of investable psychedelic opportunities in Q3 2019, the collapse of high quality cannabis investments, one of the best decembers on record and a potential $1B scale psychedelic IPO - 2020 will be the year of psychedelic investment.
The movement in the field recently is just a blip compared to what is to come, this industry has been brewing for the last few decades. Big Pharma has failed when it comes to new approaches to brain and central nervous system treatment. Neuro drugs have half the success rate of all Pharma projects, which caused most of the big players to liquidate their neuro programs in the last decade. Recently, engagement is exploding with new clinical legislature supporting neuro, the recent approval of 3 potentially blockbuster neuro drugs in the last 2 years, Q2 2019 saw a record of over $320M in investment into neuro drug development. Interestingly enough an influential group of ultra-high net worth individuals to funded the psychedelic holding company Atai Lifesciences which went on to fund Compass Pathways and continues to fund commercial efforts in this field. Atai Lifesciences recent movements are a familiar story of acquisition and consolidation in an emerging market which will be a common theme in the future of the psychedelic industry. The collapse of investable cannabis opportunities are driving investors comfortable in stigmatized industries and binary risk to the table with big pharma, cutting edge science and huge unmet market needs to create a perfect storm of opportunity.
Highlight:
Investors seek 'mega blockbuster' drugs as neuroscience undergoes renaissance
How big is the Psychedelic Industry?
Historically, the psychedelic industry has been fragmented with around $60M worth of companies in the last 20 years, many of which were not sustainable. The current industry is around $300M worth of investments, dominated by the Peter Thiel backed Atia Lifesciences at $100M+ and Compass Pathways at $50M+, followed by Mind Medicine at $10M+, Fieldtrip Ventures at $10M+ and then a 10-15 early companies in the range of $2.5-10M each. The $300M worth of investable deals have only existed since the public formation of Compass Pathways in 2016, with the majority leaving stealth mode in 2019.
Highlight:
Transforming psychedelics into mainstream medicines
How big is the Psychedelic Market?
The psychedelic market is emerging while highly coupled to clinical/regulatory events and is split between recreational and medical psychedelic markets:
Recreational: $8-19.2B
Calculated from cannabis market and comparable usage prevalence as well as demand size economics.
Medical: $373B
Calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.
Highlight: Analysis of the Psilocybin Pharmaceutical Market
Who are the players?
Atai Lifesciences - German based, Global psychedelic pharma holding company formed by ultra-high net worth individuals and big pharma, $150M+
Compass Pathways - London based psychedelic giant, Atai's bet on psilocybin as an approved drug for depression, $50M+, IPO 2020
Usona Institute - A Wisconsin based non-profit powerhouse competing with Compass Pathways to approve psilocybin for depression.
Mind Medicine - Toronto based ibogaine derived addiction drug development company taking their lead candidate 18-MC through the clinical approval process, raising $15M, RTO in 2020
Eleusis Benefit Corporation - New Orleans based discovery/clinical stage Psychedelic pharma company supported by industry scientists, raising $25M
FieldTrip Ventures - Toronto based, Aurora backed magic mushroom research and development company building clinical and production infrastructure, raising $10M+
ThinkMyco - Vancouver based holding company developing disruptive mushroom production technology and next generation therapeutics, raising $5M+
Gilgamesh - Psychedelic drug discovery company affiliated with the Atai owned Perception Neuroscience and Columbia University, raising 10M+
Universal Ibogaine - Vancouver based Ibogaine clinical development company franchising the world's most advanced ibogaine clinical model, raising $10M+, RTO in 2020
PsyGen - Alberta based psychedelic mass production and clinical research company with highly experienced production chemists $5M+
Entheogen Biosciences - Vancouver based company pursuing psilocybin and DMT based drug development, raising $3M, IPO in 2020
Salvation Botanicals - A Vancouver based company touting a private controlled substances site license and supporting clinical research, raising $10M+, RTO in 2020 Numinus Wellness - Vancouver based wellness company building testing as well as clinical infrastructure, partnered with Salvation, raising $5M+, RTO in 2020
Cybin Corp - Toronto based research and development company building drug development and production infrastructure as well as nutraceutical assets in legal jurisdictions, raising $3M
Emerging Players - There are a number of emerging players, around $25M+ in emerging deals in Q3 2019 which have not passed due diligence.
Clinical:
Recent data is showing psychedelics can be real mega blockbuster neuro drugs. Johns Hopkins recent trial on Psilocybin for smoking cessation showed an 80% success rate in terminating nicotine addiction, more than double any known therapeutic approach, including nicotine replacement therapy. Academic data shows that Ibogaine is 95% successful in terminating acute opioid withdrawal/addiction. Limited data from Ibogaine for opioid addiction trials show 50% success rates in terminating addiction, more than 10X higher than the generous 5% success rate of other approaches. Data from leading Ibogaine providers like Universal Ibogaine show that this 50% figure can be pushed closer to 75% with proper protocols and aftercare. Clinical trials on Psilocybin for cocaine/crack addiction are ongoing at the University of Alabama at Birmingham, a top 20 medical research university. 10 patients were un-blinded for bioethics review and the unpublished data shows that 30% never touched cocaine again while the other 70% had a relapse or two and turned their lives around, showing a 100% success rate in changing lives with minimal cost. When this data is available publicly in the next years, tidal waves of interest will move into the field.
Highlight:
Psychedelic Clinical Research Timeline
Projections:
As a recreational market, 0.1% of the population was surveyed as using psychedelics in the last month, placing the current black market at $19.1B while as a comparable percentage of the legal cannabis market adjusted for prevalence would place it at $8B.
As a medical market, the $373B neurogenics market seems to be the addressable market. Penetration into any indication in the neurogenics market would reap vast rewards, Psilocybin is on track to compete in the depression market with two FDA breakthrough designations, a 2% penetration into the depression market would being $1.4B in value. Ibogaines very reasonable projected 4% penetration into the opioid dependence market will bring $9.6B in value yearly to groups like Universal Ibogaine which are deploying clinical infrastructure, supporting clinical trials and controlling the Ibogaine supply chain. Of all of the indications in current psychedelic clinical trials, not considering crossover, they address a $400B+ market, with projected penetrations across each indication and adjustments for market factors, it is projected $16B+ of value yearly will be created from commercialization of current late stage clinical trials.
Highlight: Johns Hopkins Psilocybin for Smoking Cessation Data
Challenges:
Regulatory Challenges:
While nearly 100 cities are creating legislation to decriminalize psychedelics and multiple US jurisdictions have passed decriminalization, federal changes will be required to open legal markets to the full potential. While investing in the binary risk of regulatory changes is standard in the junior markets, current regulatory controls are preventing early revenues. Many Canadian companies building production and distribution infrastructure offshore in jurisdictions such as Jamaica are operating in a legal grey area. While it is legal in Jamaica, any benefit or advantage given to a Canadian company could be considered a proceed of crime including IP development, capital repatriation and validation of technology offshore. Section 56 exemptions from Health Canada are required for Canadian companies working with psychedelics offshore and companies which are raising investment dollars without a secured Section 56 exemption may be incurring legal risk.
Cardiac Liability:
The unspoken elephant in the room of psychedelic derived pharmaceutical acceptance is not regulation, for example Ketamine is a scheduled drug which was recently approved. The problem is actually the liability of bringing a seratonergic based drug to the market like Psilocybin, DMT and LSD. The crippling withdrawal of blockbuster drugs Fen-Phen and issues with other drugs like Imitrex due to seratonin agonist effects on the heart have scared the FDA into a position that any seratonergic drug will require extreme cooperation and diligence and will absolutely incur additional clinical and monitoring costs over other drugs. Psilocybin while technically hitting the 5ht2b receptor which causes cardiac side effects, does not have a high enough affinity to be a deal-breaker, meanwhile LSD having a very high affinity will cause large barriers for groups attempting to bring microdosed LSD to the market. Ibogaine suffers from cardiac liability due to an entirely different mechanism and unlike Psilocybin or LSD, adverse events have been reported. While Methadone and other standards of care also have the same long-QT cardiac liability at much higher rates and significantly higher mortality rates , Ibogaine clinical models must pre-screen patients for existing heart defects before procedures to guarantee no adverse side effects.
Banking/Insurance/Exchange Issues:
Legitimate psychedelic derived drug development companies have already had bank accounts halted at multiple banks for involvement in this industry and moving forward similar challenges faced by the cannabis industry should be expected. Exchanges and public offerings will have logistic challenges with this industry and minor friction has already been seen in the listing process. DNO insurance and other underwriting will be required to list in large markets and to date no psychedelic company has been underwritten, although underwriters and leading insurance brokers are actively exploring his industry.
Reimbursement:
The real whale will be insurance and single payer reimbursement of psychedelic derived pharmaceuticals on the market, allowing for global market uptake. Health systems have traditionally been decades behind the state of the art as seen in the point of care and home diagnostic device market, a market which could keep people healthy at minimal cost but has been crippled by lack of reimbursement.
Supply Chain Commoditization:
The production and control of psychedelic supply chains which is the familiar play of the cannabis industry will be a race to the bottom with magic mushrooms and other psychedelics. Production models are competing with a much more fluid black market and are being cannibalized by low cost home production and wildcrafting of psilocybin mushrooms. The LSD or ergoloid supply chain is highly monopolized, with the majority of the worlds ergoloids being produced in a single location.
Companies competing in the production and supply chain space will face heavy price pressure and a highly coupled global regulatory system. The single outlier is Ibogaine, with a current global use estimated around 90kg, expected to reach 280kg in the next two years, this is a commodity whose price will drive through the roof. Large ibogaine producers have stopped production and natural sources are not commercially viable, with an Iboga plant producing maybe a single dose on the 10 year period, the move of ibogaine to endangered status in 2019 and no synthetic GMP producers - the ibogaine market is legal in the majority of the world and exploding while highly underserved and fragmented.
Delivery System Challenges:
A number of recent psychedelic deals are built around new drug delivery systems for psychedelics entering the recreational market to build expertise and infrastructure ready to move into the pharmaceutical market. Many of these technological approaches will not translate from the recreational market to the pharmaceutical market such as CBD/psychedelic compositions, natural product compositions as well as vaporizer and inhaler based delivery systems. While 20%+ of all new FDA drug entities are derived from natural products, natural product mixtures containing many products and a controlled substance have never and will never be FDA approved due to the regulatory system. Companies developing Psilocybin/CBD combinations and related therapeutics for the recreational market should understand that unlike the cannabis market, recreational approaches will not translate directly to medical approaches.
Opportunities:
Syndicated Investments:
One of the largest opportunities in any emerging market is syndicated investment, a 2002 analysis of 584 venture backed exits showed that syndicated investments produced double the rate of return of non-syndicated investments. Psychedelic research and development companies require standardized infrastructure that can be leveraged across a number of players. The big players entering the industry are more interested in empire building, requiring massive consolidations of commercial efforts which can be facilitated by syndicated investment groups. Companies like ThinkMyco, Entheogen Biosciences and Cybin Corporation which focus on technology development, IP Portfolios and early stage drug discovery will benefit the most from syndicated investment and collaboration. A Harvard Business School review of Pharma discovery programs statistically compared drug discovery programs to weapons research programs and found in these high reward/low incremental cost programs the optimal path is to run parallel programs, with an average Pharma drug discovery program having 16 parallel programs, 10 core and 6 low budget/high risk.
IP Portfolio Development:
IP development is the highest value for dollar on the investment value chain and the psychedelic industry will be a totally IP driven industry. The most valuable patent portfolios will include new psychedelic compositions and therapeutic mechanisms, which require significant investments into fundamental R+D, while less competitive portfolios will include delivery system/psychedelic combinations.
A recent review of patents related to psychedelics shows many hundreds of patents for psychedelic derived therapeutics with only a small cross-section being commercially competitive. DemeRX, the $40M+ Ibogaine research company holds 65+ patents in the ibogaine therapeutic area. While DemeRX filed for bankruptcy and their research and development assets were liquidated, it is rumored they have been injected with enough capital to come back to the party - this is a dark horse to keep an eye out for.
Mushroom/Protein Connection:
The real opportunity in magic mushroom production models is flying under the radar: protein production. Mushrooms are one of the highest quality sources of nutrition and protein, if you took a vitamin C supplement you can live exclusively off mushrooms. Dried mushrooms have basically the same protein percentage as beef and in terms of grams of protein per acre per year are 100 fold higher producers and much more sustainable than traditional agricultural practices. Companies in this space which invest into real R+D for lower cost mushroom production will get a lift from the $1.8 trillion dollar protein market. A recent review of mid-sized mushroom farms shows that 50%+ of the cost of mushroom production is due to labor and technical inefficiencies. If energy, labor and materials cost drivers can be reduced, and the cost of growing a pound of mushrooms can drop from around $2 to around $1.20 through automation, mushroom protein becomes significantly more competitive than many of the industry leaders in plant based protein like pea protein. If energy cost reductions can drop the cost even further, mushrooms will become a disruptive food source. Psychedelic companies building mushroom production infrastructure will be well served to remember that by investing in automation, new technology and new growing systems the price of mushroom based protein production can make it more competitive than any other food source. The largest food security report in history was released Q2 2019 and showed that without subsidies a hamburger would cost more than 30$ and the meat industry will economically collapse by 2040, the protein game is looking more and more attractive as a hedge against the regulatory risk of magic mushroom production.
China:
China is one of the most advanced markets in terms of size and pharma spending, as well as venture investment. Traditionally the Asian cultures had no interest in marginalized and politically tense areas such as drug medicalization but the movement into CBD and China's rabid interest in plant medicines may create a large influx of Asian capital moving into psychedelics. This industry shifting action will be leveraged by education and the court of public opinion. A dialog must be created showing psilocybin as a plant medicine and not a drug of abuse. Interestingly enough, Chinese firms have very recently started producing magic mushrooms industrially and importing them into the Canadian market where they are sold into the black market over-the-counter in some Canadian herbalist stores.
Ibogaine:
Ibogaine is the only psychedelic model which will not be very quickly commoditized. Ibogaine as a solution to the opioid problem is a disruptive technology, with the rise of fentanyl and fentanyl analogs like carfentanil dominating global supply chains, Buprenorphine, the preferred standard of care is no longer effective. This is due to the aggressive affinity of fentanyl to receptors, the lack of tolerance ceiling and the little understood metabolism of next-generation fentanyl analogues, dramatically compounding a problem already at pandemic levels. Ibogaine supply chains have collapsed at the same time that demand is growing exponentially, the firm which dominates the current global ibogaine supply chain will reap around $1.4M/mo profit serving the current global demand. One of the largest African Ibogaine brokers has seen a 30x increase in sales from 2017 to 2019. With Universal Ibogaine taking Ibogaine through the Canadian clinical process and the grassroots support from Health Canada, Ibogaine will be the first psychedelic approach available to consumers. While Ibogaine is a scheduled drug in the US and some European jurisdictions, it is not scheduled in Canada and the majority of the global market. Multiple Ibogaine documentaries are in filming, including actors such as Johnny Depp, as this is an education driven industry, we should expect exponential growth to accelerate in 2020.
Support Industries:
Industries supporting the growth of psychedelics will be a large part of the future landscape as was seen in the cannabis sector. A psychedelic business support network including education, conferences, business analysis and financing have already cropped up commercially. In Q3 2019 the renowned Cambridge House International Extraordinary Future conference created a panel for psychedelic opportunities. Two weeks before the conference there was a frantic rush and the majority of relevant psychedelic players were represented last minute in the panel discussion including: Compass Pathways, FieldTrip Ventures, Mind Medicine, Johns Hopkins, Dennis McKenna and ThinkMyco. Multiple psychedelic investment funds are forming alongside of industry press, consulting groups and other support interests. In Q3 2019, Dr. Matthew Thompson of Johns Hopkins and Dr. Charles Nichols of LSU/Eleusis Benefit Corporation helped organize the inaugural conference for the new journal called International Society for Research on Psychedelics in its home of New Orleans. Over 100 international scientists from top universities were represented, with the conference having to turn down many late registrations. Dr. Rolland Griffiths, head of the Johns Hopkins Psychedelic Research Center said "This was the best scientific conference I have been to in my entire career.".
Sub-perceptual dosing:
Microdosing was popularized by Silicon Valley, catalyzing the resurgence of the psychedelic industry but microdosing is a protocol built on unsound fundamentals. Research shows that the therapeutic effects of psychedelics are highly dose dependant, higher doses lead to better therapeutic effects. The microdosing supply chain model has excellent returns, with a pound of mushrooms costing less than 5$/lb to produce which provides around 1200x microdoses. When dosages increase past the perception threshold, the potential for adverse events such as bad trips exponentially increases. The ideal dosage seems to be just under perceptual threshold where you can still go about your day, but much higher than a microdose. This is industry standard with seratonergic pharmaceuticals, an example being the diet drug Belvique, which is closely related to psilocybin, dosed at the perceptual threshold for maximum effectiveness. Belvique can cause psilocybin like hallucinations if 4 tablets are taken as it is a seratonergic drug. High doses of psilocybin require a clinical infrastructure and in-patient experience, dramatically increasing costs and logistics overheads. Sub-perceptual dosed pharmaceuticals will be available for out-patient and take home treatment and in many cases may be as effective as full blown psychedelic experiences. Mind Medicine, ThinkMyco and Eleusis Benefit Corporation are leading the charge in sub-perceptual therapeutics.
Next Generation Drug Development**:**
Mind Medicine is taking the approach of engineering the hallucinations out of the therapeutic experience by removing parts of the molecule and are moving their drug, 18-MC through the clinical process. This is the ultimate high risk/high reward play in the psychedelic industry. 18-MC is modified which also changes a variety of important receptor binding effects. The modified receptors include the receptors responsible for growth factor release, cognitive effects, cardiac effects and the opioid system coupled NMDA receptors. Since there is no data on the human use of 18-MC in opioid addicts, significant capital must be deployed before it is even known if 18-MC is as efficient as the parent molecule Ibogaine for treating opioid addiction, the ability to treat addiction in an out-patient setting with no cardiac toxicity - 18-MC will be the megablockbuster all investors in the neurogenic space are waiting for. ThinkMyco, Gilgamesh, Mind Medicine and Eleusis Benefit Corporation are leading the field in next generation drug development.
Lateral Drug Development:
While psychedelics address a $373B neurogenics market, companies such as Eleusis Benefit Corporation are showing they can address other unmet clinical needs such as chronic inflammatory disease. Eleusis is developing new psychedelic compounds for the treatment of inflammation, specifically within ophthalmology, and has recently published Phase I trial results revealing the safety and tolerability of low dose LSD in healthy older adults, with the intention of evaluating low dose LSD as a disease modifying therapy in Alzheimer's disease. Eleusis Benefit Corporation looks poised to cannibalize the $3B steroid therapeutic market. Not yet published research is showing Ibogaines potential as a therapeutic to treat sleep disorders. Johns Hopkins is currently reviewing the application of psychedelics in pulling patients from comas and vegetative states. The original pre-Mind Medicine clinical trials on the Ibogaine derivative 18-MC showed promise in treating Leishmania infection. BOL148, an inactive form of LSD, originally the placebo in human clinical LSD research, was found to in some cases to permanently terminate cluster headaches after a few doses and is being publicly demanded from the cluster headache community. These are the earliest days of understanding the application of psychedelic derived chemistry as new therapeutic approaches.
Public Health Engagement:
Looking at recently released data representing North American, working class adults, methamphetamine and fentanyl use is growing enormously and consistently. Linear regression of growth rates over the last 5 years projects a 380%+ increase in Fentanyl usage the next 15 years, with Methamphetamine projected at a 475%+ increase. This is concerning as there are more than a million high quality data points over 5 years and an R2 value of 90%+ which paints of picture of statistical certainty. This shows that the opioid crisis has moved from a lift caused by supply side drivers to an organically growing demand side driven pandemic fueled secondarily by histories cheapest and most available synthetic drugs. With $100B+ in fines projected for the opioid crisis in the next few years, state jurisdictions will shortly receive an enormous amount of cash that will be legally obligated to flow into anti-addiction spending. Due to poor outcomes and non-scalable approaches around advanced public health programs, there will be a flurry of legislature to address how to spend the $100B+ anti-addiction warchest. Players like Universal Ibogaine who have proven clinical models, can deploy infrastructure and guarantee statistically better outcomes will receive unprecedented amounts of non-dilutive government funding and will be the first to benefit from Decriminalization/Medicalization in the North American market. Players that can come to the table now at the state level and propose medicalization legislature as well as profitable clinical infrastructure with proven outcomes, could monopolize the entire US market. FieldTrip Ventures is developing Psilocybin clinical infrastructure while Universal Ibogaine is deploying proven clinical infrastructure already developed and proven by Clear Sky Recovery, the leading Ibogaine clinical experts with thousands of successful detox procedures and no critical adverse events.
Closing:
Like any emerging industry, there are challenges and growing pains but the blue-sky upside is unparalleled. "Black swan events are characterized by their extreme rarity, their severe impact, and the practice of explaining widespread failure to predict them as simple folly in hindsight." Due to changes in public opinion, a mental health and addiction pandemic as well as enormous movements of liquid cash, this sector is poised to explode in 2020.
Additional information requests: [[email protected]](mailto:[email protected])
submitted by mindovermatterlondon to Drugs [link] [comments]

Iceland - my acquaintance with the northern and moody land.

Iceland - my acquaintance with the northern and moody land.
View at Kálfafellsstaður.
Halló, hvað segirðu gott? ... This English look-a-like but still a bit cryptic phrase actually means "Hello, how are you?" in Icelandic. And if you are as much of a nature addict and a huge fan of Scandinavian landscapes as I am, you better make sure that you have Iceland on your bucket list.
I have been to this country twice and I hope to come back for more. This is kind of a country that you can't get enough of - you need regular injections of its nordic air, volcanic landscapes, ocean breeze and visions of viking history hiding in every corner. And, oooh, Iceland is totally not only Reykjavik, icelandic horses and the Blue Lagoon.

All the classic facts about Iceland can be googled so I will not go much into detail here but some points that I consider important or interesting, should be mentioned:
  • Iceland is located in the North Atlantic ocean with much land (103,000 km2 ) and not that much population (approximately 349,000) - kind of a heaven for an introvert :)
  • The country is warmed by Gulf stream and has quite a moderate climate but from my own experience of travelling there both times during winter (January and February), winter weather in Iceland is like a good roller coaster - it changes more often than my mood during the day, and I am a really mooooody person :D
  • Icelandic horses are not ponies - they are genuine horses of royal blood that you can take a ride with if you are polite enough ;)
  • Iceland has one of the most unique, diverse and picturesque nature in the world - volcanoes, black-sand beaches, glaciers, milky-blue geothermal sources, severe North Atlantic ocean waters are just a small part of it. But the country is also volcanically and geologically active! Do you remember a situation with Eyjafjallajökull eruptions in 2010 that caused a lot of disruptions to air traffic for 6 (!) days and, for sure, scared the hell out of tourists and over 500 farmers that had to be evacuated from the area nearby the volcano? That's the country where this action movie happened. There exists a suprisingly positive side of it though - this situation has resulted in a rise of the so called "volcano tourism" - a lot of people from other countries come to Iceland to look "live" at the famous Eyjafjallajökull (... I'm wondering if anyone in the world apart from Icelanders is even able to pronounce this name correctly? ). This made an increase in tourism activity and took Icelandic economy to a whole new level which was quite a suitable timing since the country experienced quite a tough recovery after the 2008 economic crisis. Way to go, Iceland! <3

Reyniskirkja with a view over Reynisfjara Beach.

My first trip to Iceland was very spontaneous - I was sitting with my friend in a bar, drinking fruit beer (yes, it exists and...it's not Coke :D) when I suddenly asked: "Do you want to take a trip to Iceland to celebrate my birthday?". My friend had no arguments against this proposal, legitimate reason/motivational factor was in place, free weekend when both of us had time and possibility was not that far from my birthday and, what's most important, prices were tolerable and tickets and hotel rooms were still available - that's how I met Iceland for the first time. And it was one of the greatest spontaneous decisions I have ever made!
This tour took place late January and the destination we were about to come to didn't promise any pleasantries of typical "South-getaway" - fortunately, we got mentally prepared some days in advance. After approximately 2 hours of enjoyment from watching "Police Academy", Icelandair drifted us through the fluffy Scandinavian clouds to the beautiful landscapes of Iceland which met us with some stormy weather and strong winds - my hair was rotating 360° and even more than it ever did during any of the hard rock concerts I've been to. But when does bad weather stop motivated travellers? First evening was spent exploring the streets and restaurants of Reykjavik - it's a city with a rather small but cozy central area, walls of which are covered with beautiful graffiti. When it comes to food, the most important for me is vegetarian possibilities, and in Reykjavik ... those are many and those are tasty!
Graffiti on the streets of Reykjavik.
The history of the Iceland's capital is not very much surprising - it's the world's northermost capital and it was the first place for permanent settelment in Iceland that has now become one of the greenest, cleanest and safest capitals in the world. I like the story about how this first settelment actually took place: around 870 AD Norsemen, led by Ingólfur Arnarsonwere drifting Northern waters when one day the time had come to decide for a place to settle. Ingólfur made a choice using a traditional Norse method: when he saw a coastline, he cast his Öndvegissúlur ... ehm ... high seat pillars and settled where they came to shore. Though rumours say that actually-actually it was all about the hot springs ... well, I would support him very much in that decision - in cruel winter conditions of the North, soaking in the warm waters with a glass of beerum and singing some good old ballads is like heaven on Earth for a hard-working viking. Well, anyway, thanks to Norsemen (and of course, to other nations that were involved at a later time phase) we, regular people, now know about and are able to soak our own limbs in the warm mineral waters of Icelandic geothermal sources ^_^
In the Geysir geothermal areas.
Next destination for us was the Blue Lagoon, which I will mention later in the post, and the Golden Circle of Iceland: Geysir geothermal area, the Gullfoss waterfall, and the UNESCO site - Þingvellir National Park. I will not get into much detail about what that places are but I would say that it's a must for a first-time traveller to Iceland - here you get the real impression of how Icelandic nature looks like: mountainious, wild, brutally beautiful and so different from the rest of Europe, with steps of past volcanic eruptions. Wandering there, among the ice and the rocks, the fields and the geysers I felt myself as the real viking ready to take onto a new adventure or to conquer some lands.
When we were standing in front of the Gullfoss waterfall that was covered with ice and steam from the water falling in the canyon of the Hvitá river, I promised myself to come at this very place when I get old, with my own comfy chair and a good book, and settle for some quality read for a couple of days or, probably, weeks. And it's easy to see why:
The Gullfoss Waterfall.
I was leaving Iceland that first time with a bunch of positive emotions, non-expiring excitement and quite a "steel"-feeling that it is not the last time I am visiting this unbelievable country. Oh my, I couldn't be more right about that feeling!
My second trip to the Nordic island was a birthday gift to my beloved one - his dream was to bathe in the waters of the Blue Lagoon and ... the least I could do was to make his wish come true and at the same time include a couple of awesome "into the wild" - getaways to get an even broader impression of Iceland and what it has to offer for two introvertic nature addicts as me and my husband :-P
View from our hotel over the Reykjavik city center.
I should say that this trip was full of adventures - pleasant and not that very pleasant so I'm not sure if I would have ever wished anyone to experience what we have experienced but I can at least share with you a story about how Icelandic Gods of Weather made us not see all the places we planned to see but made us see the places we have not planned to see at all...
The day of our arrival had probably the most wonderful weather of a total of 4 days we've been there. It was snowing a bit, and the temperature outside didn't make you think "Why the hell did I get out of my two blankets and a cozy pyjamas and went outside without an extra 5th layer of clothes?!" . So we took a tour to the Reykjavik center and had quite a tasty dinner at "Sushi social". And after that our adventures started happening.
For the next three days there have been announced storm warnings all over the country, all of different grade of severity. So our hope for that the whole-day tours that we have planned for the next two days will happen in full, became blurrier and blurrier with every gust. Our room was on the 13th floor and you know, it's a pretty unusual feeling when you are trying to sleep and your bed is at its best and dancing cha-cha-cha. And the walls are howling. And it's dark. And lonely. And scary. Well, at that moment for me it seemed like a pretty good start for a qualitative nightmare. In reality, it was not that much life threatening, the wind casts were between 18 and 25 m/s. Although we walked by a huge sign saying "Motel" that was about to fall to the ground, right onto the sidewalk...maybe that motel was not that good after all?..
The Blue Lagoon.
Our first destination on Saturday was 3-hours visit to The Blue Lagoon with the Golden Circle tour right afterwards (the same tour I took during the first trip). The weather didn't seem to be in a better mood but still, we haven't heard anything from our tourist company so we got ready for some fun and relaxation.
The Blue Lagoon. A dream place for many girls and boys, of all ages. It's maybe one of the first (and often only) things people all around the world know about Iceland. Just search for it on YouTube and you will find millions of videos from visitors and even some documentaries. I have been there twice and yes, it's absolutely worth visiting, and in my opinion, you can experience the Lagoon at its best if you visit it in winter. This feeling when you come there early in the morning, it's dark outside and you can't see a thing so you have no idea where you are, and whether it's deep geothermal waters surrounding you or just puddles. But then, suddenly, the sky gets brighter, the surroundings become more visible and you realize that you are in the middle of milky-blue waters with a thin topping of fog, warm and floating, with strong and beautiful mountains protecting this "not-so-hidden-anymore" area. And if you are lucky and it's snowing, you can experience the beauty and magic of this area even more. We were lucky in another way - the wind casts were still around 19m/s so our wine glasses tried to escape from us several times, as much as our hair. But since we were warm, had a "supermegarichwithvitaminsnutritionmask" on our faces and held a glass of wine each, the situation didn't seem that problematic after all.
So, yes, include this place in your list if you want to visit a bit diffirent kind of spa. Though, be prepared for that it may be many people there, even when it's not a high season. So if you're an introvert, especially in situations where you have only your swimming suit on, this might not be the most comfortable place to go to ;)

Stormy views on the way to Southern Iceland
After "stormy" relaxation we got excited for our tour to the heart of Icelandic nature aaaand .... here came surprise #1: due to severe storm in southwest Iceland our tour gets cancelled. That was a moment when I really wanted to do it like they do in overdramatic films: raise my fist in the sky, waive it to the weather Gods and scream "Whyyyyyy????". Unfortunately, I didn't do that. Oh, you girlish modesty! Anyway, there was nothing more we could do about it so we took our raincoats on top of our winter jackets, stormed into local Chinese bistro right across the street from our hotel, bought some Chinese food and went back to the hotel to dive under warm blanket, watch "Blue streak" and cry :D Well, it was actually a very cozy evening so maybe this tour is meant to happen when we travel to Iceland next time? ^_^

Processing img 39qhbaxoxkh21...
Fortunately, after sacrificing our tears to the weather gods they got in a better mood on Sunday and the weather calmed down a bit. It was time for the full day tour to the south coast of Iceland. And again, I will not describe it in detail because you get a lot of useful and practical information when you google the tour specifics but I need to underline that this tour is a genuine pearl of Iceland!
What may you experience during the tour?
- Mysterious black beaches of Reynisfjara and immense strength of the Atlantic Ocean waves. Seriously, we got warned that approaching the ocean too much may lead to fatal consequences - waves are so strong that if they reach you, they may drag you directly into the ocean and from there it's a "zero chance" of returning due to reefs, depth and wave speed. Though, only a few days ago I saw that some guys actually took that risk, filmed it, didn't expect a huge wave coming, got hairs on their necks raise up and ran back to the beginning of the beach like the Long Runner from the Looney Tunes.

At the beach of Reynisfjara.
- Power and tranquility of Skogafoss and Seljalandsfoss. There is a saying "Water wears away a stone" and I may definitely agree with it after I have visited these two waterfalls. When you are standing there, in front of them, watching the enourmous volumes of water break loose from the top of the mountain, with unbelievable force crashing onto the ground - that's when you realize that, in this hood, it's them who dictate the rules! Incredibly mesmerizing and meditative experience!
Seljalandsfoss.
- Vast landscapes and weather moodiness of Sólheimajökull glacier and ... tideliboom ... it's Higness - Eyjafjallajökull volcano! If you're lucky enough, the weather will change at least 5 times during the 15-20 minutes period. During our trip down to the glacier, we have experienced sun, rain, snow and hail. Something to look forward to, heh? ;) The area itself is absolutely worth it, in any weather - combination of ice and rocks, snow and volcanic ground...I bet you can still see trails lava has paved during the previous volcano eruptions.

Panorama of Sólheimajökull glacier and Eyjafjallajökull volcano.
- "Sideflowing baby waterfalls". Some weeks after we have been to Iceland I came across an article in a local newspaper where the guy filmed it and the video went viral and he became famous and started his acting career and writing books and giving autographs and and and...well, actually all I know is that he filmed this natural phenomenon and it was explained from the point of science in an article. But maybe that was the reason I have started my own blog? :D

Processing img asps8947ykh21...
- Unique chance to buy fresh Icelandic mountain air. No more words needed, it's just the best gift you can ever get. And if you don't need it yourself, I bet any person in Beijing on a very trafficked summer day will be happy to have an extra can of this at home.

Fresh. Icelandic. Mountain. Air.
That was pretty much it for the South Coast tour. The rest you should experience for yourself and I will gladly hear about your impressions from this tour! ^_^
The very last bit of my Icelandic adventures is about how to get back home when Iceland does not want you to. As I mentioned earlier, we have been so lucky to experience a good Icelandic storm while we were there but I think it's culmination fell on the day we were planning to leave. It was not that life-threatening though - the wind speed was pretty much the same as the days before - 19-20 m/s but the scenes you could see from the airport windows were like from a disaster film: empty boxes and bags flying from side to side, hopeless attempts to attach jetbridge to the plane, airport employees fighting through the wind and rain to complete any of their daily routines and ... it just wasn't happening. So our flight gets delayed for 2, 4, 6, 8 hours ...

And when we slowly start losing our hope to "flying back home for Christmas...lalala..." ... hm, no, well just getting back home on a Sunday, - around midnight we hear an announcement that we can go to boarding. Yay, a moment of satisfaction - I might actually manage to get back home and get some sleep before "the new working week clock" starts ticking! We race to the boarding gate and suddenly become part of the scene that reminded me of "The 300 Spartans" - a bunch of tired, annoyed people with "I will come back home tonight!" - adrenaline in their blood rushing their way down the stairs through lying, sitting, standing, sometimes drunk and aggressively drunk standing people who were waiting for another flight, and trying to be the first one to feel the aircraft floor under their feet.
After some scanned flight tickets though we get to hear that we will not feel the aircraft floor under our feet tonight because the flight is cancelled for good... to cut a long story short Icelandair and employees of the Keflavik International Airport have done an amazing job: though we've been waiting for a transportation and hotel in a huge queue for several hours, though we've been taken to some sacred place in the mountains, on the opposite side of Iceland, 3 hours drive from the airport and though we entered our hotel room at approximately 02:00 am, we skipped sleeping on the airport floor covered with our luggage. I have never seen employees running so fast from one corner to another, trying to pick-up people, follow them to the bus, make notes and at the same time hang on the phone with different hotels in Iceland. I love multitasking but even when I worked in Christmas time in one of the most popular restaurants in the city can't be compared to what effective multitasking these guys had in place - I'm so impressed!
https://preview.redd.it/whb7ng3jykh21.jpg?width=1259&format=pjpg&auto=webp&s=5e2e82db9c8405a452afdc20427ad7496a176635
The day after we eventually made it back home with some hours' delay. I've also made a legit excuse to get an additional day free from work, blaming the Icelandic weather gods for delaying my return.
I would really recommend to put this wonderful country closer to the top of your travel list - the nature here is so special, with its own unique personality. People here are very welcoming and proud of their country. And here are so many places for your soul to rest, to calm down, to live in the present moment, to extend your consciousness. For me at least there will definitely be several trips to Iceland but during a warmer and sunnier season, to minimize the odds of being caught in the middle of a traditional Icelandic winter storm ^_^
https://preview.redd.it/c2j09zmmykh21.jpg?width=1259&format=pjpg&auto=webp&s=6ae2f207becfe7def3c7dd6cb7837b78dadf7208
Wishing you a peaceful sky.
Sincerely yours,
guidemetothemoon
submitted by guidemetothemoon to travel [link] [comments]

Izumi3682 Archives

Have Autonomous Vehicles Hit A Roadblock? by izumi3682 in Futurology


[–]izumi3682[S] 0 points 13 days ago
If you put that little rightward pointing carot thing above the period on that keyboard key in front of your quoted statement it makes it appear a quoted statement rather than something you wrote. Like this...
Drone strikes?
Me: Well yeah, drones strikes sure. That did not occur to me first thing. What I meant was replacing 100% of human employ in all fields.
permalinksavecontextfull comments (20)editdelete
End of Human Epoch –“An AI God Will Emerge to Rule the Human Species” by izumi3682 in Futurology


[–]izumi3682[S] 1 point 13 days ago
Excellent write up in your blog post! I need to get me one of them sites lol!
permalinksavecontextfull comments (11)editdelete
Have Autonomous Vehicles Hit A Roadblock? by izumi3682 in Futurology


[–]izumi3682[S] 6 points 14 days ago
In this article every single one of these concerns is reasonable, very humanly reasonable. We fear things that are unknown quantities. Humans are ok with the "devil they know" of human caused deaths from MVAs. We don't like it, but we understand we have no choice.
Now there is going to be choice, but this is almost incomprehensibly greater than "just" saving human lives. It is going to be a "phase change" in society. And always, always bear in mind that the computing, the tracking, the mapping and the intervehicle communication is going to get more perfect with each passing year, sometimes month. E-SDVs will upgrade like your computer. And the systems that operate the E-SDVs will upgrade as well.
And like I also always say, when the "AI" can achieve perfect driving in any condition, imagine what else it can do besides drive...
permalinksavecontextfull comments (20)editdelete
Jaguar Land Rover's autonomous cars will cure motion sickness by izumi3682 in Futurology


[–]izumi3682[S] 1 point 14 days ago
As an interesting aside, it seems that researchers are thinking that motion sickness and sim (VR) sickness are the same thing even though the mechanics of how each occur are different. This could have significant impact on making prolonged VR experiences far more accessible to everyone.
permalinksavecontextfull comments (1)editdelete
Robotaxis Are Coming. So Why Are We Still So Unprepared? by izumi3682 in Futurology


[–]izumi3682[S] 2 points 14 days ago
I'm not unprepared. I have been fully aware of every single advance since 2012. But I perhaps would not have been if I had not joined into futurology. That more than anything else catalyzed my interest in what the future may bring.
permalinksavecontextfull comments (10)editdelete
End of Human Epoch –“An AI God Will Emerge to Rule the Human Species” by izumi3682 in Futurology


[–]izumi3682[S] 5 points 14 days ago
This is not hyperbole. It makes absolute logical sense. Consider what even today our super limited computing, that is perceived as the illusory artificial intelligence is capable of already. Now just add five, ten more years of that kind of monthly, sometimes weekly advance in capability.
And of course humans being humans, we will do our darndest to develop artificial general intelligence and god forbid "artificial" consciousness and self-awareness, just to see if we can. Then we will end up with a lovely EI. That's "emergent intelligence". Something that is just like us. But not precisely. It will have access to the electronics of human civilization, by virtue of it's electrical origins within a computer. I suspect that biological humans would not survive that kind of competition.
We are rapidly approaching the point that it becomes imperative that we merge the human mind with all this computing power and capacity and these so-called AI applications. If for no other reason than to keep humans minds in the loop. Surgeons are starting to forget how to do some forms of manual surgery due to robotics. Who is gonna know how to drive in twenty years? Guess who is starting to be "led"?
I see a whole slug of "soft" singularities about to happen. E-SDVs, E-SFVs (both are robots btw), VR, highly visible and ubiquitous quadrapedal and bipedal robotics, quantum computing and the biotech advances, particularly biotech that is of the cellular and molecular level of intervention. And perhaps even fusion energy and solar energy. Just the exa-scale classical computing ability alone is going to be a distinct "level up" in everything we use computers for. I am confident that in the year 2021 there will be multiple exa-scale computers operating. Humans are ambitious like that.
But the big daddy is going to be that decentralized and then suddenly (who'da thunk it!) centralized AI that, well, runs everything. That's not hyperbole. That is the logical outcome of our ARA (AI, robotics and automation) development in the next ten to twenty years. That is not very long from now. I will only be 78 my ownself in twenty years. We are all going to be here for the "technological singularity.
And it will be a human species filter, just like the possibility of an interim ARA-related social upheaval in ten years. If the "TS" is not human friendly, if the ARA remain external from the human mind, we could likely go extinct and the ARA would continue on. If the "TS" is human friendly you and me persist, but we are changed beyond anything we can imagine today.
So this is a "fire bell in the night" that humans had better had better "wake-up" and put herculean "Manhattan Project" style effort into merging our minds with computing and whatever AI evolves into, before it proceeds much further externally from the human mind. We need the "TS" to be as "human friendly" as humanly possible.
More future stuff if you are interested. I am intensely fascinated by what humans are doing now and have studied these trends closely since 2011 when it all came to my attention in the first place.
https://www.reddit.com/useizumi3682/comments/8cy6o5/izumi3682_and_the_world_of_tomorrow/
permalinksavecontextfull comments (11)editdelete
Meet Sophia: The robot who laughs, smiles and frowns just like us by izumi3682 in Futurology


[–]izumi3682[S] 1 point 15 days ago
I think most people outside of the futurology subreddit are out of touch. What I like about CNNs story is that it brings the story to the people that would not normally encounter this technical development.
Her concept is not new, but her iterations are. There are multiple "Sophias" and the device is updated almost continuously. Some iterations can ambulate bipedally without supports.
I have a strong suspicion that people outside of this subreddit are going to be taken horribly by surprise by the advances in ARA (AI, robotics and automation) in this next 5 to 10 years.
Any information they can get is helpful to my way of thinking.
I wrote this about "Sophia" just the other day.
https://www.reddit.com/Futurology/comments/9rymt3/ai_humanoid_sophia_is_granted_first_ever_robot/e8knfjg/
permalinksavecontextfull comments (4)editdelete
Magic Leap in the living room: Alone together - Augmented reality faces the same problem as VR: isolation. by izumi3682 in Futurology


[–]izumi3682[S] 1 point 15 days ago
Well, in a very real sense VR is. You can't share VR with other people in your living room unless they too are wearing an hmd and are attached to a separate VR compatible computer. Something that is probably not common in households today.
Now I am an early adopter. I got my Oculus Rift in Jun of 2016. And I had the touch controllers by November 2016. I have explored tons of VR applications. The only application that I found to be pretty acceptable social VR is "High Fidelity". And even it is extraordinarily early in it's incarnation. It receives updates several times a week. I have had extremely interesting experiences in "HF", but compared to something like real life, VR is highly socially isolating. Having said that, give VR a few more years to mature a bit. It is going to change everything.
Here is something I wrote about my VR experiences if you are interested.
https://www.reddit.com/Futurology/comments/6h7xtt/gamers_arent_buying_the_vr_hype_and_game_makers/diw60gy/
Also I have been very involved in the highly social online world of "Second Life" since 2007. I'm all about the making social experience VR a real thing.
Oh. I have extrapolated where I believe VR is going to lead if you are interested.
https://www.reddit.com/Futurology/comments/7r42h0/vr_is_going_to_be_like_nothing_the_world_has_eve
permalinksavecontextfull comments (2)editdelete
How Augmented Reality and Virtual Reality Can Revolutionize Science by izumi3682 in Futurology


[–]izumi3682[S] 2 points 15 days ago
The future's so bright I gotta wear sunglasses! :D
permalinksavecontextfull comments (3)editdelete
National Geographic is using virtual reality and social platforms to appeal to Gen Z by izumi3682 in Futurology


[–]izumi3682[S] 1 point 16 days ago
Real life imagery currently does not look good in VR. Even in full VR 3D, it looks abysmal. The resolution is why. I don't even care about the FOV. The resolution is mud. And the "screen door" effect is just adding insult to injury.
But.
The resolution is going to improve. Massively. And the FOV is going to improve as well. One of my dreams is to watch "Nat Geo VR". When the technology gets there. You will have the world at your fingertips. In jaw-dropping hi-rez 3D VR.
I don't know about you, but when it gets to that point, I'm probably not gonna want to leave. Now if you add like adult entertainment to that mix, along with the movies and videogames. You are going to have a societal addiction issue.
What a world! I can't hardly wait!! 8D
permalinksavecontextfull comments (1)editdelete
IMAX Shutters VR Experience Centre in New York, No New VR Investment in 2019 by izumi3682 in Futurology


[–]izumi3682[S] 1 point 16 days ago
I have always shook my head at this idea of centralized VR events or displays. Or rollercoasters god forbid. VR is a highly decentralized technology. It is one human being at a time. In their private living space.
Think about this. In the late 1980s and early 1990s, before there was a true internet, there was a vast "bulletin board" culture. In that culture sometimes people met and fell in love, but meeting your future spouse online in the late 1980s was considered the nadir of nerd failure in life.
Well times have changed. I bet more people are initially introduced online than in real life now.
My point is this. Right now VR is not catching on in a social sense because the experience is that of the single (pun not intended, but still made me snicker a bit when I caught it) individual experiencing the VR. As the technology rapidly improves, as the social system within VR improves, VR like them bulletin boards that evolved into the internet, will be ubiquitous. You will see concrete and well, frankly amazing new VR related innovations in the next couple of years.
But centralized VR is not a part of that.
permalinksavecontextfull comments (2)editdelete
How Augmented Reality and Virtual Reality Can Revolutionize Science by izumi3682 in Futurology


[–]izumi3682[S] 2 points 16 days ago
I don't know for sure about AR, but VR is gonna revolutionize everything. Including the human species I bet.
https://www.reddit.com/Futurology/comments/7r42h0/vr_is_going_to_be_like_nothing_the_world_has_eve
We are going to go through some comprehensive changes in the next 100 years. We will by choice become less biological and more like sentient, but non-biological entities. I see what we call VR today as a solid step in that direction. Consider the game from a few years back. It was called "No Man's Sky". It did not do that well initially but it was a massive proof of concept that we could produce a simulated universe of worlds. The procedurally generated worlds were based on a surprisingly few laws of physics to keep logic within the game, particularly regarding the appearance and function of lifeforms. I would imagine that in the next 100 years we are going to scale that up substantially. At the same time we will learn more about how the human mind works, how it perceives and how it senses. If you think about it, everything we experience is merely processed electrochemical signals. I bet we come to find out how easy it is to actually do that but with worlds that don't actually exist in reality.
One of the things I stress is that nothing happens in a vacuum. It is not VR by itself. It is not computing by itself. It is not AI by itself. It is not nanotechnology by itself. All of these are facets of the emerging super-technium that we shall derive into in the next 100 to 300 years.
As we become more and more, well, computer-like--and we will, anyone who chooses not derive in this way will simply be evolutionarily selected for extinction. They will die out of old age I guess. If they are happy with their lives, then that is all well and good.
I have to interject something here to give you insight. These ideas are not ones that humans today in 2018 would embrace. And I would not blame them. But I see steady advancement in a multitude of ways into a new civilization. The ARA is going to consume all human employ in less than 30 years. In ten years it will potentially cause a violent social upheaval if we are not institutionally prepared. Something along the lines of "post-scarcity" will be needed. So I would say you should be aware of just what elements come together to produce the future.
Probably the biggest element is going to be the "technological singularity". And it will be a human species filter, just like the possibility of social upheaval in ten years. If the "TS" is not human friendly, if the ARA (AI, robotics and automation) remain external from the human mind, we could likely go extinct and the ARA would continue on. If the "TS" is human friendly you and me persist, but we are changed beyond anything we can imagine today. I would bet that one of the changes is the ability to use our technology to produce simulated universes, literal realities of our making that we can inhabit and who knows, somebody in them may evolve their ownself. They might even have their own "TS".
What we would do in these probably hive mind created realities I don't have a clue. When you are unimaginable and unfathomable, most movie screenplays sort of go out the window.
All of this in less than 300 years I bet. If you are interested in further perspective and insight into my vision, you can take a look at this. I try to sort of sum it up, but it has ten million links to other thoughts of mine. Read as much or as little as you wish.
https://www.reddit.com/useizumi3682/comments/8cy6o5/izumi3682_and_the_world_of_tomorrow/
permalinksavecontextfull comments (3)editdelete
Palmer Luckey: 'Imminent VR Headsets Aren't Enough To Go Mainstream' by izumi3682 in Futurology


[–]izumi3682[S] 1 point 16 days ago
The Wright Bros were the first to fly. But they were quickly, within a bare three years, massively superseded by others with better designs and business models. Lord, the Wrights spent a lot of time in litigation.
The same holds true for Palmer Luckey. He was the first to develop truly consumer usable VR, but now the years are going by and his work, the Oculus Rift is in danger of being rendered nearly irrelevant now that he has shown the way.
I see the best work being done in China (PRC). Watch what the VR company Pimax does. I bet my next VR hmd is from China (PRC). They appear to be working on the technology with more dedication than the USA is.
permalinksavecontextfull comments (1)editdelete
Researchers create scalable platform for on-chip quantum emitters by izumi3682 in Futurology


[–]izumi3682[S] 1 point 16 days ago
Interesting implication.
Though tiny, the emitters are remarkably tough. "They're astonishingly stable," Strauf says. "We can cool them and warm them and disassemble the resonator and reassemble it, and they still work." Most quantum emitters must be kept chilled to -273°C but the new technology works up to -70°C. "We're not yet at room temperature," says Strauf, "but current experiments show that it's feasible to get there."
permalinksavecontextfull comments (1)editdelete
Tianhe-2 Supercomputer Works Out the Criterion for Quantum Supremacy by izumi3682 in Futurology


[–]izumi3682[S] 1 point 16 days ago
How come r computer dint do that. I thought we were 'sposed to have the best one now.
permalinksavecontextfull comments (1)editdelete
Fasten your seatbelts, the self-driving vehicle resistance is coming by izumi3682 in Futurology


[–]izumi3682[S] 5 points 16 days ago
Not from me it ain't. They utterly cannot come soon enough. I've driven for 41 years. I'm sick of driving. (Actually I'm sick of working too, but that's a comment for another day ;)
permalinksavecontextfull comments (5)editdelete
Autonomous Cars? We Want Autonomy Cars - It's the rampant dehumanization of others in a world where people think safety is something we can buy rather than the sum of choices we make. by jocker12 in Futurology


[–]izumi3682 1 point 16 days ago
E-SDV enabled level 5 autonomy is buying safety. It is also buying undreamed of convenience and ease of use.
permalinksavecontextfull comments (1)editdelete
Why Deep Learning Now? | AI Revolution Documentary by izumi3682 in Futurology


[–]izumi3682[S] 1 point 16 days ago
Wow! This is a good video. Check it out ;) (I'm the OP, but I was damn impressed by this.)
This video came out on Oct 30th 2018, but I said all of this 6 months ago.
https://www.reddit.com/useizumi3682/comments/8cy6o5/izumi3682_and_the_world_of_tomorrow/
permalinksavecontextfull comments (1)editdelete
Self-driving cars expected to shake up insurance industry by izumi3682 in Futurology


[–]izumi3682[S] 4 points 16 days ago
No, no. The business model and execution is going to literally phase change. These are going to be subscription. Post-scarcity pushing cheap subscriptions.The societal change is that within about 15 years about 80 percent of society will no longer own their own vehicle. Really that is one of the main points of the E-SDV. It is not meant to be personally owned. This is a phase change on par with the horse being replaced. The poor will vote with their pocketbooks. This is the game plan of Uber, Lyft, Apple and Waymo. Yes, even Tesla.
We may actually see the demise of many luxury or sports performance automotive manufacturers. Transport vehicles will no longer be status symbols. The way that they move and travel will obviate such needs. And there is precedent for this elimination of a status symbol. In the year 1804 Aluminum was more precious than gold. Now it's... aluminum foil. In other words a "soft singularity" in the next 15 years. But noticeable in about 5 years.
Oh and consider this...
https://www.reddit.com/Futurology/comments/8r348z/automateddriving_technology_is_starting_to_show/e0o1vy5/
permalinksavecontextfull comments (11)editdelete
Self-driving cars expected to shake up insurance industry by izumi3682 in Futurology


[–]izumi3682[S] 3 points 16 days ago
But not significantly anytime soon.
Yes, it will be anytime soon. You will see concrete declines in the death rate from human caused MVAs in about 5 years. In ten years it may be close to zero.
That kind of statement is typical of people that do not understand the exponential progress of ARA (AI, robotics and automation). The ARA is going to rapidly overwhelm human civilization. By ten years if we don't have some kind of economic alternative, E-SDVs are going to be the least of our worries.
permalinksavecontextfull comments (11)editdelete
Self-driving cars expected to shake up insurance industry by izumi3682 in Futurology


[–]izumi3682[S] 1 point 16 days ago
What? What are talking about? Perhaps English is not your first language and you don't understand the implied subtext.
permalinksavecontextfull comments (11)editdelete
Billionaires back fusion energy projects in pursuit of a ‘SpaceX moment’ by izumi3682 in Futurology


[–]izumi3682[S] 1 point 16 days ago
Hiya mr mvea!
Did you get my PM I sent about what sites might be banned?
Are some sources banned? expand allcollapse all
[–]to mvea sent 1 day ago
Hiya mr mvea!
Is nextbigfuture.come now banned? When I post from nextbigfuture there is only one view. That makes me think that nextbigfuture posts are removed?
Is Gizmodo banned. When I post from Gizmodo sites, I get an auto-ban notice. Did they change this again?
Thank you for you time! ---Izumi! :D
permalinksavecontextfull comments (2)editdelete
Self-driving cars expected to shake up insurance industry by izumi3682 in Futurology


[–]izumi3682[S] 5 points 16 days ago
Gonna shake up the funeral industry too. 37,000 USA deaths from human caused MVAs is a whopping chunk of revenue. Not to mention all the ancillary industries like flowers and stuff.
Emergency medicine to include healthy young organ donors, Body shops (for cars I mean) and local government revenue are all in trouble too.
I personally know of three humans during my lifetime that have been killed by human caused MVAs. The toll is unbearable, but we have accepted it because there has, until now, been little choice.
permalinksavecontextfull comments (11)editdelete
Ford and Baidu will develop self-driving cars together in China by izumi3682 in Futurology


[–]izumi3682[S] -1 points 16 days ago
That's right USA, any technologies that you are too faint of heart to try out here, USA companies are more than happy to go try them out in China (PRC). And China (PRC) is more than happy to try out any technology the USA is too faint of heart to try.
China (PRC) has a society and mindset that is ideal for the explosion of ARA (AI, robotics and automation). The USA is on notice.
Me and China (PRC)
https://www.reddit.com/Futurology/comments/5pwnyj/china_reminds_trump_that_supercomputing_is_a_race/dcw3qyq/
permalinksavecontextfull comments (5)editdelete
More robots to hit the aisles at Schnucks grocery stores in St. Louis area by ovirt001 in Futurology


[–]izumi3682 1 point 16 days ago
I think this is a damn good idea. When I'm at my Food Lion and I can't find my Tomato Florentine (Progresso) but there are ten thousand cans of Clam Chowder (also Progresso) instead--the system is broken. I want a robot to complain to on the spot, instead of the hassle to trying to track down the manager and get some sob story about how the distributer no longer supplies us with Tomato Florentine. And then I'd be like, but doesn't it tell you something that there are ten thousand Progresso Clam Chowders on the shelf, but no Tomato Florentine? Are people snapping up that Clam Chowder really?
Tsk! Piss on it! I just buy my Tomato Florentine (Progresso) from Amazon now. I buy a lot of my groceries from Amazon now.
submitted by izumi3682 to u/izumi3682 [link] [comments]

A Day in the Life of a Professional Gambler - Part 1 Racing's Dirty Secrets starring Brian Wright, Kieren Fallon & Dermot Browne Inside the Lives of Professional Horseplayers & Gamblers: Raw or Die Ep4- Interview w Dennis Montoro What happens when you take a professional gambler to the dog track  Can You Beat The Bookies? Racing's Dirty Secrets 2 EXPLICIT

Arguably the best film on the list, this is a clever piece of filmmaking that somehow makes a massive horse racing con not only believable but edge of the seat exciting. It’s really a tale of the two main characters and their attempts to get revenge on a slightly cartoon-like villain but it’s a hugely entertaining ride and the old-school David Milch, the storied mind also behind 'Deadwood,' changed television. Now, according to a lawsuit, the racetrack regular has lost his homes, owes the IRS $17 million and is on a $40-a-week Horse racing is a nuanced sport that consists of people and horses working together towards fame and fortune. The thrills associated with the competition have a lot of blood and sweat in the background, and that is why it remains one of the leading betting events in the world. While the Bulls documentary will cover the personal lives of those involved in the team’s run, the show is centered around basketball. Based on this review from the Hollywood Reporter, it sounds as though those already inclined to like basketball will be the ones that enjoy “The Last Dance” the most.It may not capture the attention of non-sports fans as well as the O.J. Simpson series did. This specific event was actually the inspiration behind Jordan’s book titled, “Michael & Me: Our Gambling Addiction…My Cry For Help”. A book of memoirs dedicated to his gambling shenanigans. At the end of their 10-day golf betting extravaganza, however, Jordan was able to drop the loss to around $300,000.

[index] [37308] [44804] [50668] [41183] [3524] [5264] [4175] [34780] [39502] [48559]

A Day in the Life of a Professional Gambler - Part 1

How This Man Profited $1 Billion Betting on Hong Kong Horse ... Andy Holding, professional gambler and horse racing ... The Dark Side of Sports Betting - BBC Africa Eye documentary ... A Day in the Life of a Professional Gambler... Get a copy of my "100 Year Old Horse Racing System" at the link below; http://www.winfivehundred.com/ Free tip... Former Arsenal star Paul Merson opens up to GMB about how his gambling addictions have led him to lose millions. He also responds to the level of racism in f... Drug dealing, racehorse nobbling, corrupt laying, bent bookmakers and cheating jockeys. If you want to see how corrupt British horseracing was and still is..... #BettingPeople. American Pharoah Documentary - Duration: 1:06:35. ... The Biggest Lie In Betting - Don't Place Another Bet Until You've Seen This! ... 7:41. Horse Racing Never see races like this again 2 ...